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As dyslipidaemia is a prominent CVD risk factor, improvements in its management are 
crucial, as dyslipidaemia (quantified by hypercholesterolemia and treated with statins), 
incompletely addresses the residual CVD risk attributed to non-traditional markers and 
lipoprotein subfractions. Such markers include triglycerides (TG), high-density lipoprotein 
cholesterol (HDL-C), and small- dense low-density lipoproteins. This project investigated the 
utility of the atherogenic index of plasma (AIP; log(TG/HDL-C)), as an alternative CVD risk 
marker in elderly New Zealanders. Comprehensive biostatistical and bioinformatic post-hoc 
analyses were performed on elderly cohorts of CVD patients (including coronary artery 
disease (CAD), peripheral arterial disease (PAD), stroke, and abdominal aortic aneurysm) and 
self-reported healthy controls previously recruited by the Otago Vascular Research Group. AIP 
values above a binary risk threshold (AIP > -0.039) were independently associated with an 
increased risk of CVD prevalence; however, no significant correlation between AIP and CVD 
severity was observed. Similarly, AIP values above a different binary risk threshold (AIP > 
0.12) did not independently predict 5-year outcomes (major adverse cardiovascular events or 
death) in a cohort of CAD patients with elevated CVD risk (> 10%). Likewise, the capacity 
for AIP to be modified by two acute 12-week lifestyle interventions (exercise or heat) in PAD 
patients was insignificant. Finally, AIP-associated DNA methylation biology reflected the 
existing biology for traditional lipids and cardiometabolic risk factors. DNA methylation also 
identified loci independent of traditional lipids, which suggested that this biology may be 
attributed to an independent AIP residual CVD risk beyond individual lipid markers. Overall, 
the results of this project indicate that AIP may have utility as an alternative risk marker for 
CVD risk modelling in elderly New Zealanders; however, this may be limited to assessments 
of CVD prevalence. 
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1.1 CARDIOVASCULAR DISEASE 
 
Epidemiology of cardiovascular diseases: Global 
 
The global burden of cardiovascular disease (CVD) is an increasing epidemic and public health 
concern. Between 2007 and 2017, the proportion of deaths attributed to CVD worldwide rose 
by 21.1% (95% uncertainty interval 19.7% to 22.6%), accounting for 31.8% of deaths in 2017.1 
Of the contributing phenotypes, atherosclerotic cardiovascular diseases (ACD), including 
ischaemic heart disease (IHD) and ischaemic stroke (IS) were the highest contributors, 
accounting for 84.9% of CVD-related deaths.1 As characterised previously in a comprehensive 
review by Yusuf et al.,2 non-communicable disease (NCD) prevalence is also paralleled with 
economic development and social organization. Therefore, as the most pervasive and fatal 
NCD, ACD, is synonymous with urbanization and high-income countries.2 
Epidemiology of cardiovascular diseases: New Zealand 
 
New Zealand is considered within the fourth stage of epidemiological development and as a 
consequence is subject to high rates of NCD, particularly CVD.2 Of particular note, IHD was 
the leading cause of death in New Zealand, accounting for 18% of deaths in 2012.3 However, 
since 2012/2013, the unadjusted prevalence of diagnosed IHD has decreased from 4.8% to 
4.6%, affecting 176,000 adults.4 Although a decrease was reported, any age-associated increase 
in the prevalence of IHD may be shrouded, as 22.1% of diagnosed IHD patients were those 
over 75 years of age in 2017/2018.4 
Furthermore, Yusuf et al.2 also described that certain specific subsets of a population might be 
disproportionately affected by CVD, as a component of the epidemiological transition, 
especially within New Zealand. In the 2017/2018 period alone, after adjustment for age and 
gender, the relative risk (RR) of being diagnosed with IHD for Māori vs. non- Māori, and 
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Pacific vs. non-Pacific people were 64% and 19% higher, RR 1.64 (0.23 – 11.97) and RR 1.19 
(0.16 - 8.90), respectively.4 However, pacific women may be particularly at risk given that their 
RR for IHD is equal to the Māori RR (1.64), when compared to pacific men (0.86). 
1.2 ATHEROSCLEROSIS 
 
As epidemiological shifts have driven an increased prevalence of NCD, our understanding of 
atherosclerosis has concurrently evolved.2 Presently, atherosclerosis is conceptualised as a 
chronic inflammatory disease characterised by the formation of atheroma within the arterial 
wall and can evolve into an acute clinical event by the induction of plaque rupture and 
thrombosis.5 Atherosclerosis commonly manifests in large elastic arteries (aorta, carotid and 
iliac) and preferentially at sites with low oscillatory shear stress and disturbed laminar flow 
(e.g. branch points).6 While several risk factors can trigger the development of atheroma, these 
risk factors are all centrally linked through a single process characterising atherosclerosis, 
namely, the concentration-dependent migration of low-density lipoprotein cholesterol (LDL-C) 
into the arterial sub-intima.7 
As a consequence of this process, vascular endothelial cells express adhesion molecules, which 
recruit circulating monocytes that subsequently differentiate into macrophages in the sub- 
endothelial space.8,9 The interaction of the above processes drives the subsequent formation of 
foam cells and the fatty streak, which characterises atheroma. The other consequence of these 
effects is an increased expression of inflammatory molecules resulting from the production of 
reactive oxygen species.10, 11 Collectively, these drive the secretion of various growth factors, 
which induces vascular smooth muscle migration, proliferation, and the abnormal deposition 
of extracellular matrix in progressive atherogenesis.10 
1.3 RISK PREDICTION IN CARDIOVASCULAR DISEASE 
 
Cardiovascular disease risk prediction is the cornerstone of risk prevention. As atherosclerosis 
is the pathological consequence of multiple risk factors, the identification of these risk factors 
and the quantification of their respective CVD risk has been critical for the prevention of CVD. 
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Identifying multiple risk factors for CVD has also been important because the presence or 
absence of a single risk factor may not determine the disease’s occurrence.12 Furthermore, due 
to the large degree of correlation between these factors, the interactions of risk factors can also 
work overtime multiplicatively to promote disease.13 
The advent of CVD risk prediction models has functioned as an essential tool for combining 
risk factor information to communicate the absolute risks of CVD. The Framingham risk 
algorithm (FRA), developed from the Framingham Heart Study (FHS), was the earliest risk 
model for CVD and included factors such as age, elevated blood pressure, smoking, diabetes 
mellitus, and elevated total cholesterol (TC).14 Since the advent of the FRA, research has 
elucidated other factors which have been subsequently incorporated into the FRA for use in 
primary care.15, 16 These include gender, hypertension, and dyslipidaemia. 
The New Zealand risk prediction model 
 
In 1993, New Zealand developed the world’s first national CVD risk factor management 
guidelines using multivariate risk modelling.17 These guidelines were used in concert with the 
FRA in 1991 to provide risk estimates for at-risk patient populations. Presently, the New 
Zealand risk model, PREDICT, has evolved to also encompass ethnic and socioeconomic 
diversity in contemporary New Zealand populations; including measures such as social 
deprivation and self-identified ethnicity.18 PREDICT is an electronic programme used in 
primary healthcare facilities that formulates a personalised five-year risk score for CVD–related 
events in all nationally registered 30-74-year-old males and females.18 Based on these scores, 
individuals are grouped into risk strata defined as low risk (< 5%), medium risk (5-15%) and 
high risk (> 15%) of developing CVD-related events in the next five years. Current PREDICT 
data suggests 74% of the eligible population has a <5% five-year risk of CVD, 24% have a 5– 
14% risk, and 2% have a risk of 15% or higher.19 
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Contemporary risk models lack precision: Area under the curve (AUC) 
 
Although risk modelling using personalised risk scores has improved CVD risk assessment, it 
is important to note that risk modelling still lacks necessary precision.20 Presently, 
contemporary models are unable to perfectly discriminate high vs. low-risk individuals (to 
distinguish between two or more risk subclasses).21 By definition, discrimination determines 
whether an individual will experience an outcome from those who will not20. Discriminatory 
power can be modelled using a Receiver Operating Characteristic (ROC) curve and calculating 
the area under the curve (AUC).22 The ROC curve plots the values of sensitivity (true positives) 
against 1-specificity (false negatives). Thus, the AUC reflects the risk model’s ability to 
perfectly separate cases from controls (AUC = 1.0), from being no better at detecting the 
outcome of interest (AUC = 0.5).22 In the context of CVD risk modelling, PREDICT currently 
has an AUC value = 0.73 (AUC variance 0.72 - 0.73) for both men and women. Whilst 
PREDICT’s AUC is higher than the recalibrated Framingham model in a NZ cohort,18 the 
residual risk (20-30%) unaccounted for by these models highlights that there is considerable 
room to improve these clinical tools.20 23 
1.4 IMPROVING THE RISK FACTOR PROFILE ASSOCIATED WITH CVD 
 
Given that contemporary risk modelling still lacks necessary precision, significant research has 
been performed in order to improve contemporary risk models. Multiple studies have proposed 
criteria which identifies useful markers in CVD risk modelling.12, 20 First, the factor must predict 
the occurrence of disease. Secondly, the marker must be sensitive, specific, and practical in a 
clinical setting. Thirdly, and most importantly, the factor must be an independent predictor of 
risk and improve the predictive power of other risk factors already present in risk models. 
Finally, risk factors must have the ability to inform clinical decisions as risk factor assessments 
are only useful to the extent that they affect therapeutic decision making. In this manner, 
consideration of these factors can guide the useful transition of new markers into clinical 
practice and improved patient care.12 
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1.5 REVALUATING DYSLIPIDAEMIA AS A RISK FACTOR FOR CVD 
Dyslipidaemia is a prominent CVD risk factor and perhaps the most critical component of 
atherogenesis.24 Dyslipidaemia was first identified as a risk factor in the 6-year follow-up study 
of the pioneering FHS, which established that a strong relationship between increasing serum 
total cholesterol (TC) concentrations and incident coronary artery disease (CAD) existed in 
both men and women.14 However, it was later identified that as opposed to TC alone, the 
distinction of cholesterol into its parts such as HDL-C and LDL-C, substantially improved risk 
prediction.25 
Hypercholesterolemia, either primary (familial) or secondary (acquired), is considered the 
essential component of dyslipidaemia and has a direct association with ACD progression.26 
However, the utility of dyslipidaemia, quantified by hypercholesterolemia, as a risk factor has 
recently been questioned. Historically, targeted reductions of LDL-C concentrations have been 
the primary therapeutic focus to reduce dyslipidaemia. These reductions have been seen mainly 
through the use of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin) 
therapies, in primary and secondary interventional settings. As evidence of this, a 2010 meta-
analysis of 27 statin trials in over 170,000 patients demonstrated that a 1mmol/L reduction in 
LDL-C improved the 5-year prognosis of major CVD-related events by 20%.27 However, 
despite improvements in LDL-C concentrations, many patients on statin therapies still have a 
significant “residual risk” for CVD events.28 As an example, the above meta-analysis 
demonstrated that a significant residual risk of CVD events remained, in both statin-treated 
patients (14.1%) and controls (17.8%) and represented an overall residual RR of 79%.27 This 
residual risk may also be explained by the fact that many individuals presenting at hospitals 
with CVD events do not have elevated concentrations of LDL-C, but tend to have low 
concentrations of HDL-C and elevated triglycerides (TG).29 
Collectively, this residual risk effect is concerning as statin administration for New Zealand 
patients with hypercholesterolemia has significantly increased from 8.4% in 2006/07 to 10.9% 
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(426,000 people) in 2018.4 However, this number is likely to be even larger as clinical practice 
guidelines also indicate statin therapies to patients with non-lipid disorders. Therefore, due to 
the high prevalence of statin administration, coupled with a residual risk in statin-treated 
patients, it has been questioned whether LDL-C may be a misleading risk marker of 
dyslipidaemia when LDL-C concentrations appear normal. For these reasons, considerable 
effort has been made into quantifying the lipid-associated CVD risk using markers outside of 
LDL-C. 
HDL-C and Triglycerides/Hypertriglyceridaemia as alternative lipid-risk markers 
Of the other important lipid abnormalities encompassed within the broader definition of 
dyslipidaemia, plasma HDL-C has a well-established inverse association with CVD.30 This was 
first established in the FHS and again later in a 12-year follow-up study, both of which reported 
that increases in HDL-C in men and women conveyed increased atheroprotection independent 
of LDL-C concentrations.30, 31 Furthermore, previous meta-analyses of four major prospective 
studies showed that for every 1 mg/dl (0.055 mmol/L) increase in HDL-C concentrations, there 
was a decrease in CHD risk by 2–3%, independent of LDL-C.32 Whether HDL-C itself is 
causally related to CVD risk has been contested. However, its functional role in cholesterol 
efflux from peripheral tissues and existing plaques, as well as interactions with metabolic and 
inflammatory processes, including lipid oxidation, have cemented its inverse relationship with 
CVD outcomes.32-34 
The role of hypertriglyceridaemia (HTG), has also been previously underestimated in 
atherogenesis. HTG primarily results from an increase in one or more of the triglyceride-rich 
lipoproteins; chylomicrons, VLDL, or their remnants. However, HTG may also be secondary 
to metabolic conditions such as diabetes, hypothyroidism, and chronic kidney disease.35 Similar 
to HDL-C, the independent risk association between elevated TG concentrations and CVD has 
also been contested. Several methodological considerations and the large variability between 
fasting and postprandial TG concentrations gives credence to this notion.35 This notion is also 
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supported by the fact that TG interacts with many other atherogenic conditions such as low 
HDL-C, obesity and type-2 diabetes, such that the ability to detect any independent effect, 
especially in smaller studies, has often been difficult. 
Nevertheless, data produced from meta-analyses and the EPIC-Norfolk study has provided the 
most convincing evidence supporting elevated TG concentrations as an independent risk marker 
for CVD. Specifically, fasting TG concentrations > 1.7 mmol/L, the NZ recommended TG 
concentration, were shown to have a hazard ratio for CVD of 1.63 (1.05 – 2.59) when compared 
with TG < 1.7 mmol/L.36 Moreover, as LDL-C underestimates absolute CVD risk in patients 
with HTG, it may be that TG can serve as a more significant marker for CVD beyond LDL-C, 
particularly in HTG patients.37 
Non-traditional markers of dyslipidaemia 
 
Recent research has also been conducted regarding the contributions of broader non-traditional 
markers of dyslipidaemia. These non-traditional markers account for broader aspects of 
dyslipidaemia, such as lipoprotein size and particle number, and may also account for some of 
this residual risk. These include, small dense LDL (sdLDL) and lipoprotein (a) (Lp(a)). Due 
to the constraints of this dissertation, the contribution of Lp(a) has not been discussed. Rather, 
the subsequent discussion focuses on sdLDL. However, it is important to note that the 
contribution of Lp(a) has been evaluated earlier in my literature review. 
In 1991, Krauss et al.38 identified two patterns of LDL subpopulations, based on the size and 
density of the LDL. These subpopulations were named pattern A and B. Of particular interest, 
pattern B is associated with sdLDL. Pattern B is also associated with several diseases, including 
type 2 diabetes, familial lipid, and metabolic disorders as well as obesity.39, 40 sdLDL also 
commonly presents in patients with increased TG and low HDL-C concentrations, a 
phenomenon known as the “lipid triad,” which also presents commonly in the above metabolic 
diseases. As such, the mechanisms which drive the formation of sdLDL appears to reflect the 
metabolic conditions which drive an increase in TG and reduction in HDL-C concentrations. 
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Specifically, Berneis et al.41 proposed two pathways for the formation of sdLDL based on 
hepatic TG availability and the interactions of TG and HDL-C with cholesteryl ester transfer 
protein (CETP). The first of these is that in instances where TG availability is rich, such as 
HTG, triglyceride-rich lipoproteins secreted from the liver are converted to sdLDL following 
delipidation by lipoprotein lipase and hepatic lipase. Secondly, CETP also functions to transfer 
cholesterol esters from HDL-C to very low-density lipoprotein (VLDL)/LDL and triglycerides 
in the opposite direction. In doing so, these processes directly influence the composition of 
sdLDL based on blood HDL-C concentrations and the delipidation of TG by hepatic lipase to 
form sdLDL. 
The impact of these mechanisms has been seen in more recent literature demonstrating how 
sdLDL can function as a marker for atherosclerosis. sdLDL is considered more pro-atherogenic 
than LDL-C for several reasons:42-44 Perhaps the most important of these is that the small dense 
sub-fraction contains less cholesterol. Therefore, at normal cholesterol ranges, with or without 
statins, there is an enhanced number of atherogenic particles not reflected by the concentration 
of LDL-C. Therefore, unsurprisingly, sdLDL has been demonstrated to contribute more 
significantly to atherosclerosis and CVD than LDL-C alone and has also been accepted as a 
CVD risk factor by the National Cholesterol Education Program.45, 46 Therefore, sdLDL may 
also provide additional CVD risk information in individuals with normal LDL-C 
concentrations but elevated TG and low HDL-C. This is important because patients presenting 
with dyslipidaemias outside of LDL-C are often inadequately treated. Specifically, in the 
NHANES III study, 75% of individuals with metabolic syndrome who had low HDL-C or 
elevated TG concentrations did not receive appropriate interventions in the absence of LDL-C 
concentrations outside of normal ranges.47 
Collectively, these findings demonstrate that focusing on hypercholesterolemia, and reducing 
LDL-C concentrations with statin therapies has been an overly simplistic means of addressing 
the lipid-associated CVD risk. Focussing on these aspects of dyslipidaemia also
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insufficiently reduces the residual lipid-associated CVD risk attributed to elevated 
concentrations of non-traditional lipid markers and lipoprotein fractions, such as sdLDL. 
Presently, however, quantifying non-traditional lipid markers such as sdLDL in a clinical 
setting is prohibitively expensive and challenging. Thus, as better surrogates of residual CVD 
risk, and cholesterol measures that are already obtained in a standard lipid test, a risk marker 
that encapsulates abnormalities in TG and HDL-C may serve as a more inexpensive and 
informative lipid risk marker. In turn, a marker which incorporates these measures may also be 
able to improve contemporary CVD risk modelling. 
1.6 THE POTENTIAL OF THE ATHEROGENIC INDEX IN PLASMA (AIP) 
 
The atherogenic index in plasma (AIP) is the log-transformed ratio of TG and HDL-C (log 
TG/HDL-C) and has been recently identified as a useful risk factor in CVD and may also be 
able to improve the lipid-associated CVD risk.48, 49 50-53,54, 55 
The relatively recent definition of lipid ratios has been conducted as a means of optimising the 
predictive capacity of the lipid profile.25 Lipid ratios can better reflect the metabolic and clinical 
interactions between lipid fractions and can also provide information on risk factors that are 
challenging to quantify by routine analyses. As such, these ratios provide greater predictive 
value to the lipid-associated CVD risk than isolated parameters used independently. Thus, 
increased AIP represents a CVD risk which is determined by the increase in risk subpopulations 
such as sdLDL.56 As the log ratio of TG/HDL-C, AIP produces better correlations and normal 
probability plots with these markers than the simpler TG/HDL-C ratio.54 Additionally, the 
combination of TG and HDL-C  into  a  lipid  ratio  is  not  unusual.  Whilst  the  literature  
has reported a degree of correlation between TG and HDL-C (r2 = 0.16),57 this correlation is 
relatively weak, indicating that as a combined ratio neither parameter is acting as a complete 
surrogate for the other. 
Furthermore, as the combination of TG and HDL-C, AIP is also easily calculated from a 
 
standard blood lipid profile. AIP may thus have additional utility in a clinical setting as a 
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relatively inexpensive and straightforward marker for non-traditional markers of dyslipidaemia, 
such as sdLDL. 
The utility of AIP as a surrogate risk marker for cardiovascular risk factors 
 
Whilst the literature has reported associations between AIP and CVD, AIP has also been shown 
to function as a broad marker of cardiometabolic risks. Therefore, it has been suggested that 
AIP may instead function as a surrogate marker for other risk factors, rather than a marker for 
CVD. This is particularly true for diabetes, but it is also relevant to obesity58 and 
inflammation.59 As evidence of this, a meta-analysis performed in a Chinese population has 
demonstrated that AIP best predicted the risk of developing type 2 diabetes mellitus against 
other traditional lipid markers.60 Most recently, Nie et al. proposed that AIP could also be 
implemented as a better diagnostic marker of diabetic foot osteomyelitis in a Chinese case- 
control cohort.61 Beyond the AIP relationship with diabetes, Onat et al.52 have also suggested 
that in a Turkish case-control cohort, AIP was correlated with obesity in men, as well as 
hypertension and high sensitivity C-reactive protein in women. However, the age of female 
participants and the confounding effects of menopause, make it difficult to interpret some of 
these correlation results in females, particularly those regarding inflammatory markers. 
Nevertheless, Zhan et al. has more recently demonstrated that AIP was a marker of a lipid- 
driven inflammatory state in both elderly men and women with acute coronary syndrome, 
suggesting AIP has utility as a marker of inflammatory status.59 
Interestingly, beyond this, previous studies have also suggested that AIP is inversely correlated 
with age,49, 50 perhaps the strongest CVD risk factor. Others have also shown an increasing 
association,62 or no association at all, with age.63 Accordingly, this age relationship also requires 
further investigation, particularly given that some of these studies compared case and control 
populations, which significantly differed in age, creating an ascertainment bias. 
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The utility of AIP as an independent risk factor for CVD 
Despite the strong correlations AIP has with risk factors as a broad marker of cardiometabolic 
risk, AIP has still been suggested to be a strong independent predictor of CVD risk, particularly 
CAD.49, 51, 64 A high AIP has also been reported to independently predict poorer overall 
cardiovascular health, based on the American Heart Association cardiovascular health 
metrics.65 These risk effects have been identified most evidently in Chinese cohorts, however, 
risk associations have also been identified in European52 and African53 populations. As AIP 
values greatly contrast in different ethnic populations, it has also been suggested that AIP may 
not have utility as a risk marker outside of the populations in which these risks were identified 
in19. Therefore, identifying risk associations across a range of population cohorts has been 
particularly important for cementing the utility of AIP as a risk marker. 
Beyond this, AIP has been shown to be a more sensitive and specific CVD risk marker than 
other lipid-ratio risk scores such as the Castelli risk index, the index presently used in the 
PREDICT algorithm, or traditional lipid parameters.18, 66-68 Therefore, AIP may also have utility 
as an additional component to risk models beyond the assessment of ‘conventional’ TC or LDL- 
C aspects of dyslipidaemia. This concept is further supported by the fact that AIP has the 
potential to encapsulate both independent aspects of dyslipidaemia and CVD biology, as well 
as the residual risks, such as lipoprotein particle size54 and esterification,69 hyperuricemia70, 71 
and tissue inflammation.59 
In addition to the above and perhaps most importantly, evidence has also demonstrated that the 
AIP-CVD risk effect may be independent of statin therapy. Specifically, AIP was positively 
associated with all-cause mortality in women, but not men, after adjustment for statin therapy 
in a prospective European cohort.64 This finding is important as this association was not seen 
for LDL, non-HDL, and TC concentrations. More importantly, this finding suggests that AIP 
may be an alternative, more robust, contemporary lipid risk marker in patients medicated with 
statin therapies. 
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1.7 PRESENT PROJECT 
 
The literature to date suggests that AIP may have some utility as a more informative lipid risk 
marker compared to other lipid markers, particularly the lipid ratio used in NZ CVD risk 
modelling. However, whether the AIP risk utility extends to a New Zealand population is 
currently unknown. As it has already been outlined that AIP values differ across different ethnic 
populations and thus may affect the AIP-CVD risk association, there is a need to evaluate the 
utility of AIP as a CVD risk marker in a New Zealand population. This need is also reinforced 
by the fact that modern CVD risk prediction models should be applicable to current patient 




Accordingly, this project aimed to investigate the utility of AIP as a risk marker for CVD. To 
do this, I aimed to investigate different aspects of CVD risk, using a series of elderly New 
Zealand population cohorts. Specifically, I aimed to investigate the association between AIP 
and the prevalence and severity of cardiovascular diseases. Secondly, I aimed to determine if 
baseline AIP predicts 5-year CVD events (major adverse CVD events (MACE) or death) in a 
prospective cohort of elderly NZ patients undergoing CAD assessment. Thirdly, I aimed to see 
whether AIP could be modified by an acute intervention (12 weeks of exercise or heat therapy) 
in a cohort of PAD patients. Finally, using epigenetics, I aimed to determine the underlying 
biology associated with AIP by identifying AIP-associated DNA methylation patterns using 
two independent CVD cohorts. Specific details and rationale regarding individual aims are 
discussed in subsequent chapters pertaining to those aims. Based on the current evidence, AIP 
was expected to significantly predict the prevalence, severity and subsequent outcomes of CVD, 
independent of other associated CVD risk factors. Furthermore, it was expected that AIP would 
be responsive to acute lifestyle interventions of heat therapy and exercise and would reflect 




This project was a post-hoc opportunistic investigation designed to investigate the relationship 
between AIP and CVD in a New Zealand case-control cohort observational study design. The 
investigation and analysis described in this dissertation was based on cohorts of patients 
previously recruited by the Otago Vascular Research Group (OVRG) at the University of 
Otago, Dunedin School of Medicine for their separate research into a range of cardiovascular 
diseases, including abdominal aortic aneurysm (AAA), CAD and PAD.73-75 The results 
compiled database contained demographic information and circulating lipid results from 
participants who have been recruited since 1996; however, a large portion of these participants 
have been recruited in the last ten years. Therefore, patient recruitment was previously 
conducted by members of the OVRG. These include, but were not limited to, my primary 
supervisor, Professor Greg Jones, Co-supervisor Dr. Kate Thomas, and laboratory technician 
Vicky Phillips, who were significant contributors in these processes. My involvement began in 
the data extraction, compilation, bioinformatic, and biostatistical analysis of these various 
cohorts. 
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Observational Study - CVD prevalence 
(n = 5162) 
Recruited (n = 5479) 
2.1 PARTICIPANT RECRUITMENT 
 
All study participants were recruited following the provision of written informed consent. The 
project itself was conducted under the approval of the Health and Disability Ethics Committee 
of New Zealand. All procedures conformed to the standards set by the Declaration of Helsinki. 
Participants within this project belonged to two distinct study populations. The methods 
regarding each study population are described separately. Note that, whilst there are two study 
populations, multiple studies for this project utilise subsets of patients from study population 1 
and thus have been described separately within the methods for study population 1 (Figure 1). 
The statistical analyses for both study populations have been described as a separate section at 
the end of this chapter. 














Epigenome-wide association Study 
(n = 2000) 
Observational Study – CVD severity 
Patients with CVD severity data 
PAD 
• ABI (n = 661) 
• PVR (n = 106) 
CAD 
• Coronary territories (n = 1412) 
Stroke 
• CAPB (n = 380) 
AAA 
• ASI (n = 2819) 
• AD (n = 3599) 
 
Discovery Cohort: (n = 1000) 
• 500 healthy controls and 500 
CVD patients (Male and 
Female) 
Replication Cohort: (n = 1000) 
• 500 healthy controls and 500 CVD 
patients (Male only) 
Prospective Outcomes Study 
• CAD patients with 5-year 
prospective outcomes data 
MACE and Death (n = 1021) 
 
Figure 1. Flow diagram of study population #1. 
Of the 5479 patients recruited, 5162 patients were utilised in the first observational study. Subsequently, 
subsets of this observational study cohort were used for three other studies in this project. 
Abbreviations: AAA, abdominal aortic aneurysm; ABI, Ankle brachial Index; AD, Infrarenal aortic 
diameter; ASI, aortic size index; CAD, coronary artery disease; CAPB, carotid artery plaque burden; 
MACE, Major adverse cardiac event; PAD; peripheral arterial disease; PVR, Pulse-volume recording. 
Allocated (n = 5162) 
Excluded (n = 317) 
• Not meeting inclusion criteria (n = 317) 
Allocation 
Controls (n = 958) 
CVD patients (n = 4204) 
• CAD (n = 2610) 
• PAD (n = 965) 
• Stroke (n = 558) 
• AAA (n = 1425) 
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Participant distribution and allocation within study population 1 is depicted in Figure 1. 
Participants involved in this study population were taken from the Otago vascular disease 
biorepository. As stated above, this database comprises multiple study cohorts, including a 
subset that has formed the present patient population. This population includes, but is not 
limited to, patient cohorts used in the research published by Jones et al.74, 75 The recruitment 
criteria for the patient cohorts from Jones et al. are described below. 
Collectively, 5479 patients were available for the analysis performed using study population 1. 
3214 of these patients76 were recruited from the vascular assessment laboratory (Department of 
Surgical Sciences, University of Otago) since January 2012. This cohort of patients included 
three specific sub-cohorts of patients of both sexes, all over 50 years of age, with either 
suspected CAD, PAD, carotid artery disease, or assessed as having > 10% risk of CVD event 
in 5 years by their general practitioner. Patients who had undergone coronary angiography at 
the time of recruitment (recruited between January 2012 and May 2013; n = 1032), were also 
prospectively followed for 5 years to determine whether these patients developed subsequent 
outcomes (all-cause mortality or MACE). Additionally, a fourth cohort consisting of 
individuals aged over 60 years with no self-reported history or current CVD (n = 800) were 
recruited as controls into this study. These patients were recruited by the OVRG between 
February 2006 and March 2012 from the same geographical region as the three other sub- 
cohorts, following advertisement in a local newspaper. Each of these controls also underwent a 
separate assessment to confirm an absence of IHD (including angina), PAD (confirmed by 
Ankle Brachial Pressure Index (ABPI) and carotid ultrasonography) and stroke (including 
transient ischaemic attack). 
The second cohort described by Jones et al. consisted of 1255 patients, who were recruited by 
the OVRG between January 2005 and December 2011, from the Otago region.74 Study 
participants included patients with either clinically classified CAD (n = 384), PAD (n = 262), 
Stroke (n = 184) or AAA (n = 425), as well as a control population (n = 230), recruited from 
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local Otago community groups. Collectively, this cohort was predominantly of European 
descent (> 97%) and was age and sex-matched between cases/control subgroups. 
Because study participants were drawn from multiple retrospective case-control and 
consecutive cohort studies, a significant feature of this analysis was the harmonisation of 
several CVD inclusion/exclusion criteria during the cohort aggregation process. The 
harmonisation of criteria was particularly important with regard to the combined CVD group 
and CVD-free control cohorts that were newly defined for the study. All study participants from 
both cohorts completed a detailed demographic, risk factor, and clinical history questionnaire 
to ascertain demographic risk factors. Risk factors included age, sex, history of hypertension 
and dyslipidaemia, current medication, as well as concurrent disease such as IHD, PAD, stroke, 
and diabetes. 
Patient Demographic Characteristics 
The following patient demographics and laboratory assessment data are relevant to all studies 
which have utilised patients from study population 1. Patient demographic characteristics were 
defined by specific criteria. Age, in full years, was calculated from the date of blood sampling. 
Patients were classified as having a history of IHD if they had a documented history of any of 
the following: (1) unstable angina, (2) angiographically proven coronary artery stenosis of 50% 
or greater of the vessel internal diameter in at least 1 vessel (CAD), (3) coronary interventions 
(stent or bypass) or (4) myocardial infarction (MI). History of other forms of CVD, including 
PAD, stroke and extracranial carotid disease (ECD), were also recorded. PAD was defined  as 
(1) a minimum resting ABPI < 0.7, (2) arteriography, or (3) duplex arterial scan identifying a
significant stenosis (> 50%), all with associated clinical symptoms such as claudication, pain 
during rest, or tissue loss. Stroke patients were defined as those with neurological signs and 
symptoms lasting more than 24 hours. The diagnosis was confirmed by computerised 
tomography or magnetic resonance imaging of cerebral infarction.77 The presence of internal 
carotid stenosis  (>  50%)  was  assessed  using  the  Australasian  Society  for  Ultrasound in 
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Medicine clinical protocol (D14) for colour duplex ultrasound extracranial carotid disease. 
AAA patients were defined as those with an infrarenal aortic diameter (AD) > 30 mm in men 
and > 27 mm in women, or an Aortic size index (ASI) greater than or equal to 1.5 (in both 
sexes).78 Measurements were taken as the maximum (outer wall to outer wall) diameter of the 
infrarenal abdominal aorta, and measured as the point between the renal arteries and aortic 
bifurcation in three planes (transverse, anteroposterior longitudinal and coronal) as previously 
described.75 This was determined via ultrasound imaging in our research groups vascular 
assessment laboratory by a trained sonographer. ASI was calculated as (maximum) infrarenal 
aorta diameter divided by body surface area (BSA). BSA was calculated using the DuBois 
formula79 (0.20247 × (weight (kg)0.425) × (height (m)0.725), as previously described.78 
Patients with a history of hypertension were categorised as having either a history of SBP >140 
mmHg, diastolic blood pressure > 90 mmHg, or having a history of taking a hypertensive 
medication. History of dyslipidaemia was defined as a documented medical history of 
dyslipidaemia, distinct from treatment with agents such as statins unless this treatment was 
specifically documented as being prescribed for lipid abnormality. History of diabetes was 
documented at the time of recruitment through verbal disclosure, review of patient notes and 
currently prescribed medications. Smoking status (current, ex-smoker, never) was obtained 
through verbal disclosure, in addition to the daily average number of cigarettes smoked. 
Lifetime consumption was quantified using smoking pack years, with one pack year being 20 
cigarettes (or equivalent) per day for one year. Waist and hip circumference were measured at 
the time of recruitment and used to calculate the waist-to-hip ratio (WHR). Weight, measured 
in kilograms (kg), as well as height, recorded in centimetres (cm), were obtained and combined 
in order to calculate Body Mass Index (BMI) (kg/m2). A list of currently prescribed medications 




For blood and lipid markers, a venous blood sample was collected at recruitment. EDTA plasma 
samples were stored at -80oC for future analysis, including a blood lipid profile, which was 
performed in a University of Otago accredited clinical lab. Plasma TC and TG concentrations 
were measured using Roche Diagnostics enzymatic methods. HDL-C was measured with 
Roche HDL-C plus reagents. LDL was calculated using the Friedwald formula (LDL = TC – 
(HDL-C + TG/5)).80 AIP was calculated by calculating the log ratio of triglycerides to high-
density lipoprotein cholesterol (log (TG/HDL-C)). Additionally, plasma high sensitivity C-
reactive protein (hsCRP) was also obtained in a similar manner using Roche Diagnostic 
enzymatic methods. A subset of participants also had plasma IL-1β, Il-6, IL-10, RANTES, 
and TNF-α results available. These were measured using the BioRad multiplex magnetic bead 
assays.75 Following recruitment, participants were assigned a unique de-identified code for the 
analysis process to preserve the anonymity and privacy of study participants. 
2.2.1 OBSERVATIONAL STUDY – CARDIOVASCULAR DISEASE PREVALENCE 
Of the 5479 patients available for this analysis, post recruitment application of strict quality 
control techniques resulted in the loss of 317 patients who did not meet the inclusion criteria 
described below. Therefore, a final study population of 5162 participants were used to 
investigate the utility of AIP as a risk marker for the prevalence of cardiovascular diseases. This 
cohort was then divided by CVD status into two cohorts: one with (n = 4204) and without CVD 
(n = 958). Subsequent division of the CVD group was then performed to produce specific CVD 
subgroups based on their primary CVD phenotype at time of recruitment, consisting of CAD 
(n = 2610), PAD (n = 965), Stroke (n = 558) and one with AAA (n = 1425). 
Case population classification 
 
Alongside the recruitment criteria described by Jones et al.,74, 75 the 4204 cases used in this 
study were classified in accordance with NZ cardiovascular health and management 
guidelines.19 Previous histories of other concurrent CVD phenotypes were defined at the time 
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of recruitment. These included IHD or CAD (history of MI, coronary artery 
interventions,positive imaging (angiography), PAD, ECD, Stroke, and AAA. These were 
confirmed in the participant’s medical history by confirmation of MI, vascular interventions 
(stents or bypass), positive imaging studies (angiography or duplex ultrasound with greater 
than 50% stenosis), or physiological testing (stress ECG, ABPI). AAA was confirmed with an 
abdominal ultrasound (as described below). Therefore, it was possible for participants to be 
classified as having multiple forms of CVD. Some individuals within case recruitment groups 
were found not to reach the primary case inclusion thresholds and had no prior history of 
CVD. Such individuals were excluded from further analysis. For example, a participant 
recruited in the consecutive coronary angiography cohort who subsequently had no 
documented angiographic coronary lesions (0 vessel disease), or prior history of coronary 
intervention, would not have been classified as having CAD. Additionally, if a patient had no 
previous history of other forms of CVD, they were excluded from the analysis. 
Control population classification 
 
The 958 controls used in this study were selected based on strict inclusion and exclusion criteria. 
These controls were all over 60 years of age and self-identified as having no history of IHD 
(including angina), PAD and stroke (including transient ischaemic attack). Each participant 
underwent an abdominal ultrasound scan to exclude AAA, and bilateral carotid ultrasound 
scans to exclude carotid artery disease. For this dissertation, a thorough post recruitment review 
was conducted, and control participants were excluded for further analysis if their recruitment 
questionnaire (with medical history review) or recruitment ultrasound scan documented arterial 
disease (CAD, PAD, AAA, Stroke, ECD, or Thoracic abdominal aneurysm). 
2.2.2 OBSERVATIONAL STUDY – CARDIOVASCULAR DISEASE SEVERITY 
 
For the separate analysis investigating whether AIP correlated with the severity of different 
forms of CVD (CAD, PAD, Stroke, and AAA), several measures of disease severity were also 
recorded. These included: ABPI, PVR, Coronary artery disease severity, carotid artery plaque 




Of the 5162 patients available for this analysis, patients had matching AIP data with: ABPI (n 
 
= 661), PVR (n = 106), coronary artery disease severity (n = 1412), CAPB (n = 1569), ASI (n 
 
= 2819) and AD (n = 3599; Figure 1). Using these measures, CVD case subgroups, as defined 
in section 2.2.1, were re-classified as follows: PAD - PAD patients with resting ABPI < 0.9 and 
without diabetes (n = 456). Those who had diabetes were excluded and analysed as a separate 
cohort (n = 106), using PVR as a semi-quantitative index of disease severity. This is because 
ABPI values are not a reliable measurement of PAD in diabetic patients.81 CAD - CAD patients 
with data for single, double, or triple vessel disease (n = 1412). Double or triple vessel disease 
was quantified as angiographically proven coronary artery stenosis of 50% or greater of the 
vessel internal diameter in 2 or more vessels. Stroke - Stroke or ECD patients with carotid artery 
plaque burden values (expressed as percent stenosis) 1-15% or greater (n = 380). It was possible 
for patients to have stenosis below the primary case inclusion threshold (< 50%), for the same 
reasons stated in 2.2.1 or because of a difference in classification criteria for stroke used 
between respective cohorts prior to their harmonisation in the present study. AAA - AAA 
patients with ASI values > 1.5 (n = 557) and AD values (> 30mm in men and > 27mm in 
women; n = 1239). 
Patient Demographic Characteristics 
 
Measures of ABPI, PVR, CAD severity, ASI, and AD are consistent with that described in 
section 2.2. Additionally, CAPB was quantified using ultrasound imaging and expressed as 
percent stenosis. 
2.2.3 PROSPECTIVE OUTCOMES STUDY 
 
As described in 2.2, a subset of the recruited population (n = 1032) who have previously 
undergone coronary angiography and had an elevated 5-year CVD event risk (>10%) were 
available to determine if AIP at the time of recruitment predicts subsequent events (MACE or 
death). Using 1021 patients from this cohort, AIP was entered as a new outcome variable to 
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determine whether these prospectively recruited patients developed subsequent MACE or 
death over the 5-year follow up period. MACE and Death data were collected by others, under 
the then supervision of Dr. Sean Coffey, a consultant cardiologist. MACE was defined 
according to the American College of Cardiology/American Heart Association Key Data 
Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials document.82 
For the analysis in this dissertation, any MACE was aggregated into a binary value (yes) along 
with the number of days following initial recruitment. The three outcomes that were analysed 
were (1) any MACE (excluding death; MACE (no Death)), (2) Death (all-cause), and 
(3) any MACE or death. A fourth subgroup, no MACE or Death, was also created and analysed 
as the control population. 
2.2.4 EPIGENOME-WIDE ASSOCIATION STUDY 
Finally, a subset of patient plasma samples from 2.2 (n = 2000) with DNA methylation 
expression data were analysed for the epigenetic analysis of AIP. This analysis was performed 
1) to uncover the biology of AIP and 2) to determine whether there was any concordance 
between the DNA methylation biology and the epidemiology of AIP with CVD risk factors. A 
Genomics Aotearoa Bioinformatician has performed all prior analyses to those described in 
this dissertation. Under supervision, a basic literature search and composite of gene 
ontology (GO) enrichment and pathway enrichment analysis of differentially methylated 
CpG sites associated with AIP was performed. The methods for these analyses are listed below. 
The same analysis was performed for both discovery and replication cohorts. 
Cohorts 
Data from two cohorts were explored: 1) a discovery cohort consisting of male and female CVD 
patients, and 2) an independent replication cohort consisting of a separate population of male 
CVD patients. Approximately 500 healthy CVD cases and controls were included in the 
discovery analysis. Samples from these patients have been analysed using the Illumina Human 
450 Bead Chip. Likewise, the replication cohort consisted of an entirely independent cohort of 
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500 healthy controls and 500 CVD patients. Samples obtained from these patients were 
analysed using the Illumina EPIC array. 
Meta-analyses 
To determine whether AIP was reflecting the existing DNA methylation biology for traditional 
blood lipids and cardiometabolic risk factors, a literature search of prominent papers 
documenting established epigenetic markers associated with individual lipids was performed. 
Collated evidence from meta-analyses and systematic reviews regarding lipid traits, metabolic 
disorders, chronic low-grade inflammation, and cigarette smoking was investigated. Replicated 
gene terms identified in the present study were cross-correlated with the gene terms previously 
published in these findings. 
GO enrichment/Pathway Analysis 
GO enrichment analysis and pathway enrichment analysis using the Metascape online GO tool 
was performed to investigate enriched GO terms and biological pathways associated with AIP 
differentially methylated CpG sites.89 Gene ontology achieves this as a bioinformatic tool 
designed as a computational representation of biological systems. A GO annotation is an 
association between a specific gene product and a GO concept, together making a statement 
pertinent to the function of that gene. To do this, GO considers three distinct terms of how gene 
functions can be described: molecular function, cellular component, and biological process. 
Likewise, pathway enrichment analysis is a computer representation of the biological system. 
In Metascape, pathway enrichment can be performed on several collections of gene sets. 
Reactome, KEGG, and DAVID were initially investigated, however, because the coverage of 
genes in each collection was low for several of these databases, this study has focussed on GO 
and Reactome. Reactome is distinctive from other manual annotation databases as it focusses 
its manual annotation effort on a single species, Homo sapiens, by applying a single consistent 
data model across all of these domains of biology.83 
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2.3 STUDY POPULATION 2 
 
2.3.1 INTERVENTION STUDY 
 
To investigate the effects of two acute lifestyle interventions on AIP, a second study population, 
consisting of patients who have participated in a previous randomised control trial (RCT), was 
used. Specifically, this study previously investigated the effects of hot water immersion therapy 
or supervised exercise therapy in PAD patients (n = 18).84 Patient flow through the study 
protocol is depicted in Figure 2. Only those methods regarding the present analysis have been 
included. The full study protocol is listed in Akerman et al.84 
 
 
Figure 2. Flow diagram of study population #2. 
Taken with permission from Akerman et al. 
 
In brief, the study population itself consisted of individuals recruited after clinical assessment 
for PAD at the vascular assessment laboratory (Department of Surgical Sciences, University of 
Otago), who had mild to moderate intermittent claudication who were not being offered 
revascularisation. Patients were clinically assessed using two separate ABPI measurements; at 
rest and following treadmill exercise (3 min, 3.0 km/h, 10% incline). The presence of an 
abnormal ABPI, consistent with that described in section 2.2.1, was confirmed using duplex 




Patients were randomised to one of two treatment groups: heat therapy (n = 8) or supervised 
exercise therapy (n = 10). Exercise: Patients randomised to the exercise therapy joined a 
supervised exercise group that was held 2 days/week, which represented the current standard 
conservative care for PAD. This group was supervised by a physiotherapist with > 20 years of 
experience in this role. Exercise consisted of 30 min of self-paced walking on a 30m marked 
course, followed by 60 min of self-selected circuit exercises in the hospital gym. Heat: Patients 
randomised to heat therapy attended an aquatic facility 3–5 days/week at the School of Physical 
Education, Sport, and Exercise Sciences, University of Otago. Heat therapy consisted of 
supervised spa bathing at ~39°C for a progressive duration. Participants were encouraged to 
maintain immersion depth to shoulder height as tolerated. The lowest level of immersion was 
to the xiphoid process. 
Main experimental procedures were completed during at least two separate sessions and 
separated by ≥1 day. All assessments were standardised within participants for multiple 
measures, including the time of day, food and fluid intake, prior physical activity, caffeine, and 
nicotine intake. 
Comparing Outcomes of Heat Versus Exercise 
 
To compare the effectiveness of heat therapy to supervised exercise, all participants completed 
measurements of functional walking ability (primary outcome) and resting blood pressure 
(secondary outcome). These measurements were completed during the week before the 12- 
week intervention and again during the week after it was completed. 
Walking test: All participants completed supervised 6-min walk tests around a 30m course, in 
duplicate, 20 min apart. Pain-free walking distance was recorded upon self-reported pain onset. 
The maximum walking distance with the 6-min test was also recorded. 
Blood Pressure: Manual BP measurements were obtained from the left arm in triplicate on 2 
separate days. MAP was calculated as one-third systolic (SBP) plus two-thirds diastolic blood 
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pressure (DBP) for all BP measurements and reported as the average of all available 
measurements to improve reliability. 
Laboratory Assessments 
 
Whole blood samples were collected and centrifuged immediately at 4°C for 10 min at 3,000 
rpm. Subsequently, plasma was then stored at -80°C for batch analysis. Lipid and inflammatory 
parameters, including plasma TG and HDL-C, as well as hsCRP, were obtained using similar 
methods with that described earlier in section 2.2. AIP was calculated by calculating the 10- 
based logarithm of TG to HDL-C (log (TG/HDL-C)). 
2.4 STATISTICAL ANALYSIS 
 
The statistical approaches used to calculate demographic and clinical characteristics are 
consistent across both study populations. However, as a representative example, the approaches 
used have been described once in full for the first study in 2.4.1. P < 0.05 was considered 
statistically significant for all statistical analysis. 
2.4.1 OBSERVATIONAL STUDY – CARDIOVASCULAR DISEASE PREVALENCE 
 
Demographic and Clinical Characteristics 
 
Continuous data are expressed as mean ± standard deviation or presented as median (inter- 
quartile range) for continuous data with a non-Gaussian distribution. Categorical variables have 
been expressed as a percentage (%). Baseline characteristics were compared using one-way 
ANOVA (for normally distributed variables) or Mann-Whitney U-test to determine differences 




Correlations between AIP and CVD risk factors were calculated using Spearman rank 
correlation tests. Spearman rank correlation tests were chosen as a conservative non-parametric 
approach for analysing relationships between CVD risk factors. Correlation coefficients 
between AIP and categorical risk factors were obtained by assigning an integer value of 1 to 
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patients who were yes/positive and 0 to patients who were no/negative for the risk factor, 
respectively. Integer values were subsequently plotted as a continuous outcome variable vs. 
AIP as the continuous independent variable. 
LOWESS Regression 
 
Locally weighted scatterplot smoothing (LOWESS) least squares regression was performed to 
visualise the relationship between AIP and CVD, where the assumption of linearity could not 
be met using linear regression. Cases and controls were assigned an integer value of 0-1, 
respectively. Subsequently, integer values were expressed as a continuous probability as the 
dependent variable vs. AIP as the continuous independent variable. 
ROC analysis 
 
ROC analysis was performed to identify optimal binary AIP cut-offs for any-CVD, and all 
individual forms of CVD, by identifying the value that maximised sensitivity and specificity. 
ROC analysis was also performed to identify optimal binary cut-offs for other lipid parameters 
and to test the discriminatory ability of all lipid parameters for CVD. All lipid parameters (TG, 
HDL-C, TC/HDL-C, and AIP) were entered as continuous variables. Case-control status was 
defined as yes/positive and no/negative, respectively, for discriminating patient states. The 
utility of using ROC has been implicated in clinical epidemiology to quantify how accurately 
medical diagnostic tests can discriminate between two patient states.85 
Logistical regression 
 
The independent risk association between AIP and CVD was examined using stepwise 
logistical regression. Combined any-CVD (CAD, PAD, Stroke, or AAA), and individual forms 
of CVD, were entered as separate outcome variables into the logistical regression model. Using 
the AIP risk cut-offs established from ROC, AIP was entered as the primary independent 
variable. AIP values below the cut-off were used as the reference group for the analysis. 
Multiple logistic regression analysis (using a forward stepwise procedure, model fit criterion P 
< 0.15)) was performed to determine if univariate associations between AIP and any-CVD, or 
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individual forms of CVD, were independent of the interactive effects of other known CVD risk 
factors, such as age, sex, history of smoking, diabetes, dyslipidaemia and hypertension. The 
basic model was adjusted for age and sex. Risk factors were added sequentially into the model 
in order of most to least significance based on the univariate logistical regression. Covariates 
were removed from the model if they could not retain significance (P < 0.15) on the addition 
of other covariates. A separate logistic regression model, using available risk factors used in 
the PREDICT algorithm, was also generated to simulate the effect of AIP in a population risk 
model and to ensure the effects seen in the stepwise regression were reflective of all known 
contributing risk factors for CVD. A separate non-diabetic subgroup analysis adjusted for age 
and sex was also performed to isolate any effect of AIP on CVD, independent of diabetes. 




Spearman rank correlation tests were performed to analyse correlations between AIP and 
continuous measures of disease severity (ABPI < 0.9, ASI and AD). Kruskal-Wallis tests were 
performed for multiple group comparisons to assess differences between AIP and non- 
continuous measures of disease severity (PVR, CAD severity, and CAPB). Mann-Whitney U- 
tests were also performed for 2-group comparisons. AIP was expressed as a continuous variable 
throughout the analyses. 
2.4.3 PROSPECTIVE OUTCOMES STUDY 
 
Correlation Analysis - LOWESS Regression 
 
First, LOWESS regression was performed to visualise the association between AIP and MACE. 
The methods involved in this analysis were consistent with the LOWESS regression described 




ROC curve analysis was performed to identify the optimal AIP binary cut-off for MACE by 
identifying the value that maximised sensitivity and specificity. Unlike that described in 2.4.1, 
MACE and No MACE or Death, as opposed to case-control status, was defined as yes/positive 
and no/negative, respectively, for discriminating patient states. 
Logistical regression 
 
Univariate and multiple logistic regression was performed (using a forward stepwise procedure, 
model fit criterion P < 0.15) to determine whether patients with AIP values above the binary 
cut-off identified from ROC analysis had an increased risk of MACE. MACE was the outcome 
variable of interest. AIP was the primary predictor variable. The basic model adjusted for age 
and sex. A separate stepwise model adjusted for diabetes alone was also fitted prior to the 
addition of other covariates to quantify any diabetes-independent AIP-MACE risk. A non- 
diabetic subgroup analysis was also performed to validate any risk effect seen after adjusting 
for diabetes alone. Multiple logistic regression was then performed by adding risk factors to the 
model sequentially, in order of most to least significance, based on the univariate logistical 
regression. As was the case in 2.4.1, a separate logistic regression model using available risk 
factors also used in the PREDICT algorithm was generated. 
Cox proportional Hazards Regression 
 
The prognostic associations between AIP and MACE were modelled using Cox proportional 
hazards regression. Multivariable stepwise Cox models were constructed in an identical manner 
to the logistical regression above. Covariates considered for multivariable Cox models included 
age, sex, TC, WC, hsCRP (excluding > 20), statin therapy, a history of diabetes, dyslipidaemia, 
hypertension, and smoking. The Cox model fit was assessed based on whether the addition of 
a covariate improved the overall chi-squared statistic. Follow-up time was censored on the date 
of event ascertainment. Participants who did not have an event were censored at the end of the 
follow-up period. After fitting Cox regression models, the proportional hazards assumption was 
tested for AIP risk groups on the basis of Schoenfeld residuals. 
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2.4.4 EPIGENOME-WIDE ASSOCIATION STUDY 
 
Metascape GO enrichment and Pathway analysis 
 
To identify enriched GO terms and pathways associated with AIP, gene terms that met a 
stringent threshold of P < .0001 (n = 115) in the discovery cohort were included in the analysis. 
Likewise, in the replication cohort, gene terms of P < 1.0E-5 (n = 73) were included in the 
analysis and were mapped to each term of the respective GO and Reactome databases using the 
Metascape online GO tool. These cut-offs were an arbitrary estimate; to pick a sufficient 
number of most significant genes. Subsequently, the overrepresentation test was performed to 
identify significantly enriched GO terms against a genome background (Homo Sapien). Terms 
with a P < 0.01, a minimum count of 3, and an enrichment factor > 1.5 (the enrichment factor 
is the ratio between the observed counts and the counts expected by chance) were collected 
and grouped into clusters based on their membership similarities. More specifically, P-values 
were calculated based on the accumulative hypergeometric distribution,86 and q-values were 
calculated using the Benjamini-Hochberg procedure to account for multiple testing.87 Kappa 
scores88 were used as the similarity metric when performing hierarchical clustering on the 
enriched terms, and sub-trees with a similarity of > 0.3 were considered a cluster. The most 
statistically significant term within a cluster was chosen to represent the cluster. 
2.4.5 INTERVENTION STUDY 
 
A student’s paired t-test was performed to compare differences in AIP values before and after 
12-week interventions of respective heat and exercise treatments. Treatment groups were 
analysed individually and combined to provide a comparison of the entire study population as 
a whole. 
All analyses performed for AIP were also repeated for TG and HDL-C throughout each chapter, 
with the exception of Chapter 7, which was only performed for AIP. Statistical analysis was 
performed with StatView® version 5.01 (SAS Institute, Cary, North Carolina, USA), MedCalc 




THE ASSOCIATION BETWEEN AIP AND THE PREVALENCE OF 
CARDIOVASCULAR DISEASE 
 
Consistent with the methods described in 2.2.1, a total of 5162 individuals (4204 cases and 958 
controls) were included in the analysis. The rationale supporting the investigation of this chapter 
has been previously discussed in section 1.6 of Chapter 1. This chapter is an exception to other 





Baseline CVD risk profiles of Case and control groups 
 
Baseline demographics, clinical characteristics and laboratory data are shown in Table 1. Full 
demographic data for individual CVD subgroups has been displayed in Supplementary Table I. 
Compared to the control population, patients with “any-CVD” (any of CAD, PAD, Stroke or 
AAA; Cases) had significantly higher AIP values. With the exception of male sex and waist to 
hip ratio, all other demographics and clinical characteristics were significantly elevated in cases 
compared to controls. Interestingly TC exhibited a paradoxical association with CVD, 
exhibiting higher TC values in the control population compared to the case population. 
Note that, demographic data for inflammatory markers was analysed as a separate subgroup in 
Table 1, as a smaller proportion of patients had this data. This data was only analysed as the 
any-CVD combined cohort. Additionally, as high CRP reflects acute inflammation (typically 
related to infection) and therefore does not represent underlying chronic (mild) inflammation 
that may reflect the ‘inflammation’ associated with atherosclerosis, hsCRP values >20 mg/L 
were excluded from our analysis. 
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Table 1. Baseline Demographic and clinical characteristics of case and control groups. 
 Control 
n = 958 
Case (any-CVD) 
n = 4204 
P-value 
Age, years 69.0 (65.0 – 74.0) 71.0 (63.0 – 78.0) .0026 
Sex, males % 68.6% 70.0% .3809 
History hypertension, % 26.9% 61.1% <.0001 
History diabetes, % 5.3% 17.9% <.0001 
History dyslipidaemia, 
% 
25.9% 59.4% <.0001 
BMI 26.2 ± 3.7 27.6 ± 5.4 <.0001 
Waist (cm) 95.9 ± 11.1 98.0 ± 12.9 <.0001 
Waist hip ratio 0.9 ± 0.1 0.9 ± 0.1 .1067 
Pack years 0.0 (0.0 – 15.0) 17.5 (0 – 37.5) <.0001 
Smoking Status    
Never smoked, % 49.6% 26.6% <.0001 
Ex-Smoker 1 - 20 pack 
years, % 
26.4% 20.4% <.0001 
Ex-Smoker > 20 pack 
years, % 
18.3% 36.0% <.0001 
Current Smoker, % 3.8% 15.0% <.0001 
Blood lipids    
Total Cholesterol, mmol/L 5.3 ± 1.1 4.7 ± 1.2 <.0001 
HDL-C, mmol/L 1.4 ± 0.4 1.2 ± 0.4 <.0001 
TG, mmol/L 1.4 (1.0 – 2.0) 1.6 (1.2 – 2.3) <.0001 
AIP 0.04 ± 0.28 0.18 ± 0.29 <.0001 
    
Inflammatory marker Control 
n = 711 
Case (any-CVD) 
n = 1154 
P-value 
IL-1β, mg/mL 12.3 (8.7 – 17.2) 15.5 (9.9 – 22.5) <.0001 
IL-6, mg/mL 45.2 (31.9 – 63.7) 60.0 (39.7 - 87.3) <.0001 
IL-10, mg/mL 62.3 (39.0 – 100.4) 81.2 (49.8 – 125.0) <.0001 
RANTES, mg/mL 16324 (11155 – 29621) 19006 (11531 – 43688) <.0001 
TNF-α, mg/mL 264.6 (198.0 – 387.6) 336.8 (225.7 – 484.7) <.0001 
hsCRP (excluding > 20 
mg/L) 
1.5 (0.7 – 2.9) 2.7 (1.3 – 5.7) <.0001 
Continuous data is expressed as means ± standard deviation or median (interquartile range), with 
respective P-values being from one-way ANOVA or Mann-Whitney U-test. Nominal data is shown as 
percentage (%) and P-values calculated using Chi-squared tests. P < .05 was considered significant. 
 
Compared to the control population, mean AIP values were significantly higher in the case population 
with any-CVD. With the exception of male sex and waist to hip ratio, all other demographics and clinical 
characteristics were also significantly elevated in cases compared to controls. Interestingly, total 
cholesterol exhibited a paradoxical association with case status, as TC concentrations were significantly 
lower in the case population. 
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The relationship between AIP, TC and Statins 
 
As TC exhibited a paradoxical association with CVD, and to elucidate whether AIP may be a 
robust marker in the presence of statins, a sub-analysis was performed to determine the effect 
of statin treatment on baseline values of blood lipids. As the cohorts of patients used in this 
study have been collected since 1996, the guidelines for the prescription of statin medication 
may have changed over the period of patient recruitment. As such, the medicated statin 
population may represent patients beyond those with lipid abnormalities being treated for 
dyslipidaemia. Because of this, this study did not conduct a full sub analysis on statin exposure, 
instead only sought to quantify the effect that statins had on components of the lipid profile 
itself. 
Irrespective of case-control status, patients medicated with statins had significantly lower TC 
concentrations compared to non-medicated statin patients (Supplementary Figure I). By 
contrast, AIP values were not significantly different across medicated and non-medicated statin 
patients in either cases or controls. Interestingly, HDL-C concentrations were decreased in the 
statin-medicated case patients compared to the non-medicated case patients. Nevertheless, these 
findings suggest that while statins significantly reduce TC concentrations and HDL-C 
concentrations in cases, they may have a less pronounced effect on AIP. 
Correlations between AIP and cardiovascular disease risk factors 
 
Spearman rank correlations between AIP and CVD risk factors are depicted in Table 2. Across 
continuous risk factors, AIP was positively correlated with BMI, WC, TG, and hsCRP 
(excluding values > 20mg/L; hsCRP excluding > 20) in both case and control cohorts. AIP was 
inversely correlated with HDL-C across both case and control cohorts. Interestingly, in the case 
population only, AIP was inversely associated with age and positively correlated with TC 
concentrations. Additionally, of the categorical risk factors, AIP was positively correlated with 
a history of diabetes, hypertension, dyslipidaemia and smoking (increasing with the duration of 
smoking), in case and control cohorts. Of these risk factors, AIP values were also most strongly 
33  
correlated with a history of diabetes. No inflammatory markers, with the exception of hsCRP 
(excluding > 20), were significantly correlated with AIP. Therefore hsCRP (excluding > 20) 
was subsequently used as a representative marker of inflammatory status. Additionally, as WC 
was the most strongly correlated measure of adiposity with AIP, WC was used as the 
representative adiposity measure for further analysis. 
Moreover, there was a distinct difference in the size of the correlation values between TG and 
AIP in case and control populations. Specifically, the correlation value was more than four- 
times greater in the case cohort that the control cohort (0.882 vs 0.201, respectively: Table 2). 
Interestingly, this relationship was not seen when comparing correlation values for HDL-C and 
AIP in the same cohorts. This suggested that the elevated AIP values seen across CVD case 
populations may be more strongly driven by plasma concentrations of TG. Collectively, these 
results suggest AIP is positively associated with most CVD risk factors, with the exception of 
age and HDL-C concentrations which were negatively correlated with AIP. 
Table 2. Correlations coefficients between AIP and CVD risk factors. 
 Control 
n = 958 
Case (any-CVD) 
n = 4204 
(Rho) P (Rho) P 
Continuous risk factors     
Age, years -0.01 .9404 -0.11 <.0001 
BMI 0.30 <.0001 0.32 <.0001 
Waist, cm 0.34 <.0001 0.33 <.0001 
Blood lipids  
Total Cholesterol, mmol/L 0.03 .3397 0.07 .0340 
HDL-C, mmol/L -0.76 <.0001 -0.74 <.0001 
TG, mmol/L 0.20 <.0001 0.88 <.0001 
hsCRP (excluding > 20) 0.20 <.0001 0.17 <.0001 
Categorical risk factors     
History hypertension 0.30 <.0001 0.17 <.0001 
History diabetes 0.46 <.0001 0.37 <.0001 
History dyslipidaemia 0.25 <.0001 0.19 <.0001 
Smoking 
Ex-Smoker 1 - 20 pack years 


















Data are expressed as Rho (ρ) values (Spearman rank correlation), with respective P-values. P < .05 was 
considered significant. There were positive correlations between AIP and most risk factors, except for 
inverse correlations with age in the cases and HDL-C in both controls and cases, and no correlation 
between AIP and either age or TC in the control population. 
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The relationship between AIP and cardiovascular disease(s) 
 
As AIP was correlated with most CVD risk factors, particularly in cases, LOWESS regression 
was performed to investigate the relationship between AIP and CVD. The decision to use 
LOWESS regression, as opposed to linear regression, was made based on conditions where 
the assumption of linearity could not be met. Examination of the case cohort suggested that a 
positive relationship existed between AIP and the prevalence of CVD (Figure 3). The slope of 
this relationship was not linear and appeared to differ in patients with positive or negative AIP 
values. Both of these relationships were also broadly observed across individual forms of 
CVD and did not appear to be driven by male or female sex, or diabetic status, as this 
relationship was observed in a non-diabetic cohort (Figure 3, Supplementary Figure II). This 
suggested that AIP had a broad positive association across all forms of CVD, which was 
independent of sex and diabetes. Moreover, because AIP was broadly and positively associated 
with all forms of CVD, the subsequent analysis focussed on any-CVD as a representative 
outcome variable. 
The optimal AIP value for discriminating CVD 
 
Next, ROC analysis was performed to identify the optimal AIP binary cut-off for discriminating 
cases from controls at the value which maximised sensitivity and specificity (Table 3). At a C- 
statistic equal to 0.626, AIP discriminated patients with any-CVD at a binary cut-off value of - 
0.039. This cut-off was associated with a sensitivity and specificity of 76.16 and 42.86, 
respectively. This value resulted in 1411 patients being classified below and 3750 patients 
above this cut-off. Importantly, this was the optimal AIP value that could be achieved with this 
dataset. Moreover, with the exception of PAD, this cut-off was not dissimilar to other respective 
cut-offs obtained for individual forms of CVD. Therefore, whilst a separate binary cut-off may 
be required for patients with PAD, this suggested that the AIP cut-off value obtained for any- 
CVD was an acceptably representable binary threshold for defining CVD status. As such, this 












Figure 3. Locally weighted smoothed scatterplot showing the relationship between the AIP and cardiovascular disease prevalence. 
(A) AIP values were positively associated with the probability of having any-CVD in the combined any-CVD cohort (n = 5162). This relationship was distinct between 
positive and negative AIP values, where negative AIP values appeared to have a greater influence on the probability of CVD. (B) The relationship identified in A was 

















Table 3. Receiver operating characteristics (ROC) analysis for AIP and forms of cardiovascular 
disease (with matching ROC curve for any CVD vs. control). 
CVD cohorts C-statistic (95% CI) Cut-off Sensitivity Specificity P-value 
CVD vs control (n = 5162) 0.626 (0.613 - 0.639) -0.039 76.16 42.86 <.0001 
CAD vs control (n = 3565) 0.632 (0.616 - 0.648) -0.039 76.96 42.69 <.0001 
PAD vs control (n = 1925) 0.621 (0.599 - 0.643) 0.136 54.40 64.82 <.0001 
Stroke vs control (n = 1488) 0.635 (0.610 - 0.659) -0.037 77.55 42.90 <.0001 
AAA vs control (n = 2383) 0.643 (0.624 - 0.663) -0.037 78.88 42.80 <.0001 
Data reported as C-statistic (95% CI) with respective P-values. AIP significantly discriminated 
combined any-CVD and all individual forms of CVD. With the exception of PAD, the binary cut- 
offs associated with the respective C-statistics were similar across individual forms of CVD. 
 
Any CVD vs Control 
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The independent association between AIP and Cardiovascular disease 
 
Subsequently, the independence of the relationship between AIP and any-CVD with that of 
other risk factors was investigated using stepwise logistical regression. The raw unadjusted and 
adjusted odds ratios (OR) are represented in Table 4 using individuals with AIP values <-0.039 
as the reference group. In the univariate logistical analysis, high AIP values (AIP > -0.039) 
were independently associated with any-CVD. After adjusting for significant risk factors 
including diabetes, dyslipidaemia and smoking in a more fully adjusted step-wise model, 
patients with high AIP values had a twofold chance of having any-CVD compared to those with 
low AIP values (OR 2.0). To ensure the stepwise model was not failing to account for any risk 
effect from risk factors not included in the model, another model incorporating all available 
risk factors used in the PREDICT algorithm was created. High AIP remained a strong 
independent risk factor in this model (OR 2.6). This elevated risk was also broadly consistent 
across all individual forms of CVD (Supplementary Table II). 
A non-diabetic subgroup analysis (n = 4311) was also performed to confirm the diabetic- 
independent AIP-CVD risk association. This was important because 1) the literature in Chapter 
1 described AIP to be a diagnostic marker for diabetes and 2) diabetes was the risk factor most 
strongly correlated with AIP in the correlation analysis (not accounting for TG or HDL-C). AIP 
values were also elevated in diabetic patients compared to non-diabetic patients 
(Supplementary Table III). Importantly, in the same adjusted logistic regression models as 
above, high AIP was independently associated with any-CVD and all individual forms of CVD 
in the non-diabetic cohort (any-CVD = OR 2.5; Table 4, Supplementary Table IV). 
Collectively, these findings suggested that AIP was a strong broad independent CVD risk 
marker, independent of diabetes. 
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A direct comparison between AIP, TG, HDL-C and TC/HDL-C 
 
A final sub-analysis was performed to establish whether AIP was a more informative risk 
marker than TG, the TC/HDL-C ratio and HDL-C lipid parameters. As depicted in Table 5, 
ROC analysis demonstrated that at a C-statistic of 0.587 and 0.634, respectively, TG and HDL- 
C significantly discriminated patients with any-CVD. Of the lipid markers investigated, HDL- 
C had the highest discriminatory power at a cut-off of 1.14 mmol/L (C = 0.634). This C-statistic 
was marginally greater than that obtained for AIP. The HDL-C cut-off also encapsulated 2589 
patients below and 2572 patients above this cut-off, suggesting this cut-off also encapsulated 
equal proportions of the study cohort above and below this cut-off. Interestingly, the TC/HDL- 
C ratio was the only lipid parameter unable to significantly discriminate any-CVD patients (C 
= 0.505). However, as stated above, this was likely an effect of statins on the TC lipid fraction. 
As such, I did not include this ratio in the subsequent analysis of lipid parameters. 
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Table 4. Multiple logistic regression for lipid parameters associated with any cardiovascular 
disease. 
 
 Probability of any-CVD 
Unadjusted model OR (95% CI) P-value 
TG > 1.49 mmol/L 1.8 (1.5 – 2.0) <.0001 
HDL-C < 1.14 mmol/L 2.3 (2.0 – 2.7) <.0001 
AIP > -0.039 2.4 (2.1 – 2.8) <.0001 
Model 1   
TG > 1.49 mmol/L 1.8 (1.6 – 2.1) <.0001 
HDL-C < 1.14 mmol/L 2.4 (2.1 – 2.8) <.0001 
AIP > -0.039 2.4 (2.1 – 2.8) <.0001 
Model 2   
TG > 1.49 mmol/L 2.0 (1.6 – 2.7) <.0001 
HDL-C < 1.14 mmol/L 1.9 (1.4 – 2.4) .0001 
AIP > -0.039 2.5 (1.8 – 3.2) <.0001 
Model 3   
TG > 1.49 mmol/L 2.1 (1.6 – 2.7) <.0001 
HDL-C < 1.14 mmol/L 2.1 (1.6 – 2.7) <.0001 
AIP > -0.039 2.6 (2.0 – 3.4) <.0001 
Model 4   
AIP > -0.039 1.3 (0.9 – 1.9) .1143 
Model 5 (non-diabetic)   
TG > 1.49 mmol/L 2.1 (1.6 – 2.8) <.0001 
HDL-C < 1.14 mmol/L 1.8 (1.4 – 2.4) <.0001 
AIP > -0.039 2.5 (1.9 – 3.3) <.0001 
P <.05 was considered significant versus low AIP (< -0.039), low TG (< 1.49 mmol/L) and high HDL- 
C (> 1.14 mmol/L). 
Data reported as odds-ratios (OR; 95% CI), with respective P-values. High AIP (> -0.039), low HDL- 
C (< 1.14 mmol/L and high TG (> 1.49 mmol/L) concentrations all independently predicted any-CVD 
in unadjusted, and all adjusted stepwise logistical regression models, including a risk model mirroring 
PREDICT (Model 3). Further adjustment for both TG and HDL-C (continuous) removed the AIP 
independent risk effect (Model 4). 
Model 1 - Adjusted for age and sex. 
Model 2 - Adjusted for a history of diabetes, hypertension, smoking, WC, hsCRP (excluding 
>20), TC and statin therapy. 
Model 3 - Model 2 further adjusted for a history of dyslipidaemia, age and sex. 
Model 4 - Model 2 further adjusted for HDL-C and TG (continuous). 
Model 5 - Model 2 in a non-diabetic cohort. 
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Multiple Logistical regression 
 
Using their respective binary thresholds, the magnitude of the risk associations for any-CVD 
between high AIP, high TG and low HDL-C were compared (Table 4). Both TG and HDL-C 
were significant independent predictors of any-CVD in unadjusted and adjusted stepwise 
logistical regression models. At the unadjusted level, the magnitude of the AIP risk association 
with any-CVD was greater than TG alone, however, the risk association was similar to HDL- 
C. Interestingly, the magnitude of any-CVD risk was largest for AIP in the multivariable 
stepwise logistical model, despite a small degree of overlap in the confidence intervals of all 
three lipid parameters. This was also evident in the non-diabetic cohort. This suggested that 
whilst AIP had the greatest risk effect for any-CVD of all three lipid parameters, TG and HDL- 
C were also equally effective independent markers for any-CVD. 
Independence of TG and HDL-C 
 
Finally, HDL-C and TG were inserted into the AIP logistical model for any-CVD. Whilst this 
may seem unconventional, this was performed to demonstrate whether high AIP values were 
accounting for a residual CVD risk beyond TG and HDL-C (Table 4). Whilst the independent 
risk effect that high AIP values had for any-CVD was insignificant when HDL-C and TG (as 
continuous variables) were included into the AIP risk model, some risk effect was still observed 
(Table 4). Nevertheless, because this risk effect was insignificant, this suggested that AIP may 
not be capturing any additional residual risk for any-CVD, beyond TG and HDL-C in this study. 






P < .05 was considered statistically significant. All lipid parameters, except the TC/HDL-C ratio had 
significant discriminatory power for CVD. AIP and HDL-C had the highest discriminatory power. The 
cut-off value for AIP, which maximised sensitivity and specificity was an AIP = -0.039. Likewise, the 
cut-off values for TG and HDL-C were 1.76 and 1.15, respectively. 
 AUC (95% CI) Cut-off Sensitivity Specificity P-value 
CVD vs control      
AIP 0.625 (0.612 – 0.639) -0.039 76.16 42.69 <.0001 
TG, mmol/L 0.587 (0.574 – 0.601) 1.48 57.32 56.99 <.0001 
HDL-C, mmol/L 0.634 (0.621 – 0.647) 1.14 52.84 67.95 <.0001 





This study assessed the utility of AIP as a contemporary and routinely available risk marker for 
the prevalence of multiple forms of cardiovascular disease (CAD, PAD, Stroke, and AAA) in 
a series of elderly population cohorts. Consistent with other reports, AIP values were elevated 
in patients with CVD and highly correlated with many CVD risk factors. Additionally, at a 
binary risk cut-off of AIP equal to -0.039, high AIP values were robustly and independently 
associated with the prevalence of any-CVD.54,65 Importantly, this association was not specific 
to any one form of CVD or appeared to be greatly influenced by exposure to either statin 
treatment or other prominent CVD risk factors, particularly diabetes. 
As described in Chapter 1, there is a need to identify contemporary lipid risk markers outside 
of those which account for LDL-C, due to the residual risk phenomenon which remains in these 
patients, resulting from statin treatment.90 As expected, statin medication was a significant 
confounder of the LDL-C-CVD risk association in this study. More importantly, statin 
medication did not affect AIP values significantly between case-control cohorts, or the AIP- 
CVD risk relationship when statins were included in the AIP logistical model. This finding is 
in agreement with a previously reported statin-independent relationship between AIP and CVD 
mortality in women.64 In addition, this study has identified a statin-independent CVD risk effect 
in a combined cohort of elderly men and women, suggesting that, at least, the statin-independent 
AIP-CVD risk relationship may not be sex-specific. This finding also supports the utility of 
AIP as a more robust and routinely available lipid risk marker. 
Our ROC curve analysis also demonstrated that the TC/HDL-C ratio had a lower discriminatory 
power when compared to AIP. To reiterate, the discriminatory power of diagnostic markers for 
CVD is particularly important in risk prediction. High discriminatory power, reflected by a 
large AUC or C-statistic, indicates a risk markers ability to perfectly discriminate cases from 
controls (AUC = 1.0), from being no better at detecting the outcome of interest (AUC = 0.5).22 
Furthermore, a large AUC ensures individuals are not falsely discriminated as having the 
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disease when they are disease-free (false-positives) or vice-versa (false-negatives).22 The C- 
statistic associated with the TC/HDL-C ratio was = 0.505. Therefore, it was evident that the 
discriminatory power of the TC/HDL-C ratio appeared to be no greater than chance alone, 
undermining the utility of the TC/HDL-C ratio as a contemporary diagnostic risk marker. It 
was also observed that the discriminatory power of AIP was a significant improvement of the 
TC/HDL-C ratio for CVD (AUC = 0.625). While this discriminatory power is not perfect, the 
existing literature has not implicated AIP to be the best marker for CVD prediction. What this 
finding does suggest, is that as a diagnostic marker, AIP appears to have utility as an 
improvement on the existing lipid ratio used in PREDICT; albeit at a minimal increase.18 
Multiple logistical regression also suggested that patients with an AIP above a binary risk cut- 
off equal to -0.039 were independently associated with the risk of CVD across all investigated 
forms of CVD. It is noteworthy that in a clinical context, an AIP greater and less than 0, as 
opposed to -0.039, would still function as an acceptable and more practical risk cut-off. 
Furthermore, the independent risk associations using a binary AIP cut-off were also consistent 
with earlier reports, particularly those that have established risk associations with CAD and 
have been identified predominantly in non-European populations.49, 52, 63 This study has also 
produced novel findings regarding the AIP risk association with other forms of CVD such as 
Stroke and AAA. Of these forms, it was surprising to see such a robust association with AAA. 
Unlike other forms of vascular disease, AAA is a different form of atherosclerotic CVD 
(dilating phenotype, as opposed to a stenotic phenotype). Additionally, as highlighted in a meta- 
analysis of serum lipoproteins and AAA, the role of dyslipidaemias in the pathogenesis of AAA 
is equivocal, based on the evaluation of lipid-lowering treatments. Moreover, the role of 
dyslipidaemias in AAA has also been focussed on an inverse association attributed to higher 
HDL-C concentrations.91 Nevertheless, after adjustment for traditional risk factors, including 
statin medication, and a separate sub-analysis performed in a non-diabetic cohort, patients with 
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a high AIP had a greater than twofold increase in risk for AAA (OR = 2.1) and all other forms 
of CVD. 
The non-diabetic sub-analysis performed in this study was essential, due to the known strong 
diagnostic relationship between AIP and diabetes, and the independent risk relationship 
diabetes has with CVD.92 Diabetes has a strong effect on the risk profile for CVD, particularly 
CAD92. Diabetes also induces oxidative stress and metabolic processes, which contribute to 
endothelial dysfunction and progressive atherogenesis.93 Therefore, it was possible that out of 
the risk factors AIP was highly correlated with, the AIP-CVD risk association may have been 
a surrogate effect for diabetes. Nevertheless, our non-diabetic sub analysis demonstrated that 
AIP was a broad, robust risk marker for all investigated forms of CVD, independent of a 
diabetic risk effect. 
Perhaps the most interesting finding from this study was that AIP did not appear to account for 
a residual CVD risk beyond individual TG and HDL-C lipid parameters when these factors 
were incorporated in the logistic regression. The current research has implicated AIP to have 
greater utility as a risk marker beyond conventional lipid parameters for CVD or all-cause 
mortality.50, 67, 68, 94 In part, this risk is thought to be attributed to an independent residual risk 
captured through the AIP relationship with lipoprotein size,54 esterification rate,69 and other 
independent CVD risks beyond individual HDL-C, TG or TC concentrations.49, 51, 64 In the 
absence of data on esterification rates, lipoprotein particle size and number, it was not possible 
to confirm whether AIP had a relationship with these components and whether these 
components were eliciting any risk effect in this study. However, the inclusion of both TG and 
HDL-C into the AIP model was an available alternative to test this hypothesis by method of 
exclusion. While there was an observed risk effect after the adjustment for TG and HDL-C, 
which was trending toward significance, this did not appear to be independent of TG and HDL- 
C. Therefore, regardless of the mechanisms for which AIP may have a residual risk effect, it is 
not clear whether this residual risk is significantly contributing to the AIP risk association in 
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this study and requires further investigation. Identifying any potential residual risk is also 
important because HDL-C appeared to have a similar discriminatory power for any-CVD 
compared to AIP in this study. Nevertheless, based on the magnitude of the risk effect for CVD, 
AIP appeared to have the greatest risk effect for any-CVD compared to individual lipid 
concentrations, suggesting AIP may be communicating a greater amount of risk information. 
3.3 STRENGTHS AND LIMITATIONS 
 
The multiple independent cohort study design, large statistical power, and consistency of 
findings with that of other independent reports, has reinforced the robust association found 
between AIP and CVD in this study. Due to the nature of patient recruitment, there was a degree 
of ascertainment bias in classifying certain risk populations. Additionally, the retrospective 
study design, the limited access to certain demographic data, and other measures of broader 
lipid characteristics, including statin indications, may have affected the interpretation of these 
results, particularly the HDL-C-statin effect. 
Furthermore, certain limitations influence the output of LOWESS regression when dealing with 
smaller patient numbers, which was apparent for individual forms of CVD, such as PAD. 
However, as the associations identified in these plots were accounted for by the logistical 
regression, this suggested the observed associations were not a result of the mathematical limits 
of the LOWESS regression output. Finally, this study was performed in an elderly European 
NZ population > 50 years; a group at a greater risk of CVD. As such, the implications of these 




In conclusion, this study indicates that AIP is a broad and independent risk marker for 
cardiovascular disease in elderly New Zealand patients. Whether this risk-utility is greater than 
the independent effects of TG and HDL-C alone requires further investigation. However, AIP 
appears to have utility as a risk marker with greater discriminatory power beyond the TC/HDL- 
C ratio and a larger risk effect for CVD compared to TG and HDL-C. Therefore, AIP may have 








In the previous chapter, it was established that AIP may have utility as a broad independent risk 
marker for the prevalence of cardiovascular diseases. Therefore, as an extension of this 
predictive utility, this study aimed to assess whether AIP could be used as a marker for the 
severity of cardiovascular diseases. 
Recent evidence has suggested that AIP may play a role in the progression of more severe CVD 
by proxy, due to the AIP relationship with cholesterol esterification; a top indicator of CAD 
progression.95 Interestingly, the literature to date regarding the AIP relationship with disease 
severity has been centred on CAD. Presently, three papers have investigated the relationship 
between AIP and CAD severity. Ni et al. showed that AIP values were elevated in male patients 
with multivessel lesions compared to a CAD-free control population, however, this difference 
was not observed when comparing patients with single and multi-vessel lesions.96 Conversely, 
Wu et al. and Bittner et al. both demonstrated that AIP was strongly correlated with CAD 
severity in women using Gensini score (GS) as an index of CAD severity.50, 97 The conflicting 
nature of these findings suggests that the AIP relationship with CAD severity requires further 
investigation, particularly with reference to a female sex effect. Additionally, as there is a 
paucity of evidence investigating the association between AIP and the severity of other CVD 
phenotypes, there was an opportunity to investigate this in the present study. 
Accordingly, this chapter reports the results for the correlation analysis between AIP and 
patients with measures of disease severity specific for CAD, carotid disease, PAD and AAA. 
These measures included, coronary artery disease severity, CAPB, ABPI, PVR, AD and ASI, 




Does AIP correlate with the severity of PAD? 
 
First, the relationship between AIP and PAD severity was investigated. Spearman rank 
correlation analysis suggested that no significant relationship existed between AIP and ABPI < 
0.9 (Rho = 0.017; P = 0.71) in the entire cohort of non-diabetic patients or in specific sex 
subgroups (Men; Rho = 0.05, P = 0.42, Women; Rho = -0.04, P = 0.59). Additionally, Kruskal- 
Wallis tests suggested that in the diabetic cohort AIP was not significantly associated with PVR 
(H = 1.56; P = 0.66) or in specific sex sub-groups (Men; H = 1.10; P = 0.66, Women; H = 0.68; 
P = 0.66). Separate correlation analyses were also performed between TG and HDL-C with 
ABPI and PVR. Neither TG (Rho = 0.02; P = 0.74) nor HDL-C (Rho = -0.01; P = 0.87) were 
significantly correlated with ABPI in the non-diabetic population or male or female sex 
subgroups. Similarly, no significant association between TG (H = 1.25; P = 0.74) or HDL-C (H 
= 2.73; P = 0.43) concentrations and PVR was observed in the diabetic cohort, or after 
investigating this association in sex subgroups ((Men TG; H = 2.84; P = 0.42, Men HDL-C; H 
= 4.11, P = 0.25) (Women TG; H = 1.23; P = 0.75; Women HDL-C; H = 0.51; P = 0.92)). This 
 
suggested AIP was not correlated with PAD severity. 
 
Does AIP correlate with the severity of Coronary artery disease? 
 
Next, correlations between AIP and CAD severity were investigated. Kruskal-Wallis tests 
suggested that AIP values were not correlated with CAD severity in the entire cohort (H = 1.78; 
P = 0.41; Supplementary Figure III), sex subgroups (Men; H =2.20, P = 0.33: Women; H = 
3.40, P = 0.18) or in a non-diabetic cohort (H = 0.66; P = 0.72). However, a significant increase 
in AIP values across all severity groups compared to the control group was observed 
(Supplementary Figure III). Additionally, neither TG nor HDL-C were correlated with CAD 
severity in the entire cohort (TG, H = 0.88; P = 0.64; HDL-C, H = 0.88; P = 0.18), sex subgroups 
((Men TG; H = 3.26; P = 0.19, Men HDL-C; H = 0.48, P = 0.78) (Women TG; H = 3.33; P = 
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0.19; Women HDL-C; H = 1.61; P = 0.44)) or in the non-diabetic cohort (TG; H = 0.57, P = 
0.75: HDL-C: H = 2.23, P = 0.33). As such, AIP did not appear to be correlated CAD severity. 
Does AIP correlate with the severity of Carotid disease? 
Subsequently, the relationship between AIP and CAPB was investigated. Kruskal-Wallis tests 
suggested AIP values were not significantly associated with the severity of carotid stenosis in 
the entire cohort (H = 8.03; P = 0.15; Figure 4). However, there appeared to be a male-specific 
association between AIP and CAPB (H = 13.82; P < 0.01; Figure 4). This male sex effect was 
also reflected for TG and HDL-C (TG; H = 11.67; P < 0.03: HDL-C; H = 11.49, P < 0.04). 
Interestingly, however, further investigation demonstrated the differences in AIP values to be 
specific to patients with 70-79% stenosis who had lower AIP values then patients with 50-69% 
stenosis (P < 0.02). AIP values were also greater in patients with occluded vessels compared 
to those with 80-99% stenosis (P < 0.03). Therefore, it is not clear whether AIP is clearly 
correlated with the severity of carotid stenosis. 
Does AIP correlate with the severity of Abdominal Aortic Aneurysm? 
 
Finally, correlation analysis between AIP and AAA severity, using ASI and AD, was 
investigated. Spearman rank correlation tests suggested that a weak negative correlation may 
exist between AIP and ASI (Rho = -0.08, P = 0.07). Moreover, this may be more specific to 
male, but not female sex (M; Rho = -0.09, P = 0.06: F; Rho = -0.06, P = 0.53) and did not 
appear to be influenced by diabetes (Non-diabetic; Rho = -0.07, P = 0.10). Additionally, TG 
appeared to have a very weak negative correlation with ASI (Rho = -0.09, P < 0.03), which was 
not reflected when assessing correlations with HDL-C and ASI (Rho = 0.04, P = 0.32). 
By contrast, AIP was not correlated with AD (Rho = 0.03, P = 0.35). Unlike ASI, the 
classification for AAA using AD is based on sex-specific thresholds. Therefore, we assessed 
the correlation with AD and AIP at these thresholds, however, there was no observed sex-effect 
(Men; Rho = 0.03, P = 0.38: Women; Rho = -0.01, P = 0.93). Similarly, there was no significant 
degree of correlation between AIP and AD in the non-diabetic cohort (Rho = 0.02, P = 0.47) or 
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when investigating this correlation for TG (Rho = 0.01, P = 0.84 or HDL-C (Rho = 0.05, P = 
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Figure 4. Box plot demonstrating the relationship between AIP and Carotid disease. 
(A) In the entire cohort, there were no observable differences in AIP values across carotid 
stenosis strata (P = 0.15). (B) In men, AIP values were significantly different across carotid 
stenosis strata. Specifically, patients with occluded carotid arteries had higher AIP than 
those with 80-99% occluded vessels (P <0.01). Likewise, patients with 70-79% stenosis had 
lower AIP than those with 50-69% occluded vessels (P <0.01). Kruskal-Wallis tests were 
used for multiple group comparisons. 2-group comparisons were using a Mann-Whitney U- 
test. *P <.05 
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In this chapter, a series of elderly patients presenting with CAD, PAD, Stroke, and AAA were 
examined to determine whether AIP was correlated with the severity of these respective CVDs. 
AIP did not appear to be significantly correlated with the severity of CVDs measured using 
indices such as ABPI, PVR, CAPB, CAD severity ASI, and AD. 
To date, the literature investigating the AIP relationship with CVD severity has been centred 
around CAD.50, 96, 98-100 However, correlations between AIP and CAD severity have been 
specific to female sex and have been quantified using the GS; a different measure of CAD 
severity to the present study.101 Of the two papers that have established correlations, Bittner et 
al. also demonstrated this correlation to be independent of a comprehensive list of traditional 
risk factors.97 
A difference in methodologies is important to consider because the GS accommodates a more 
considerable heterogeneity in CAD presentations compared to the scoring method used in this 
study and Ni et al.96 The heterogeneity is captured by factors such as severity score, region and 
presence/absence of collateral vessels when grading the severity of a lesion. As a consequence, 
it is possible to attain the same severity score from different CAD presentations when compared 
to other scoring methods. For example, here, CAD severity was assessed based on the presence 
of angiographically confirmed CAD (> 50% stenosis) in one, two, or three or more coronary 
territories. Therefore, multiple lesions in only one coronary artery territory (like the RCA) 
would be considered single vessel disease in our study; however, it would contribute to a 
different and possibly higher severity score using the GS. As the data collection for these 
patients was performed prior to this study, future work would benefit from re-analysing this 
data, using the GS. This would evaluate whether the findings in Wu et al. and Bittner et al. were 
indicative of a true association, particularly for women. 
The present study was also the first group to investigate correlations between AIP and other 
 
measures of severity (ABPI, PVR, ASI, AD, and CAPB). In the absence of any robust result 
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between AIP and these other severity measures, it is difficult to interpret the true meaning of 
these findings. Nevertheless, this study can infer that diabetes does not appear to be determining 
the relationship between AIP and CVD severity, as the observed correlations were not 
significantly different in our non-diabetic sub-analysis. 
The correlation analysis between AIP and the severity of carotid disease in stroke patients, 
measured by CAPB, demonstrated a weak male-specific association between AIP and CAPB. 
As this result also appeared for TG and HDL-C concentrations, it suggested AIP may be 
associated with the severity of carotid disease. However, as the two observed differences in AIP 
values between CAPB strata were in opposite directions, this finding was misleading and 
suggestive of a correlation that was more likely a result of a type-I error. As such, AIP does not 
appear to be correlated with the severity of carotid disease in an elderly New Zealand cohort of 
stroke patients. 
Finally, the correlation analysis between AIP and AAA severity demonstrated that a weak 
negative trending effect between AIP and ASI might exist. By comparison, no correlation 
between AIP with AD was observed. As touched on in Chapter 3, separate to other forms of 
stenotic disease, AAA is considered a dilating phenotype. As such, the results regarding the 
correlation between AIP and AAA may have a degree of independence from the factors 
involved in stenotic diseases such as PAD, CAD, and Stroke. 
Recently, a paper published by Jones et al. highlighted the importance of accounting for body 
surface measurements as a part of AAA screening.78 Measures such as ASI, which accounts for 
body surface area, may be more accurate in detecting AAA as opposed to absolute aortic 
diameters, particularly in smaller individuals, who may fall below the aneurysmal detection 
threshold, but could still have an enlarged aorta relative to their normal size. As such, the 
association between AIP and ASI may more accurately reflect the AIP relationship with AAA 
in this study. Nevertheless, given this was only a trending effect and not indicative of any real 
association, it suggests that even if AIP was shown to be a marker for aneurysmal growth rate 
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in a more greatly powered study, it is unlikely to be a more informative marker compared to 
other more prominent risk factors for AAA, such as smoking, age, and hypertension.102 
4.4 STRENGTHS AND LIMITATIONS 
 
The strengths of this study were access to large patient cohorts with available clinical data on a 
range of measures used to quantify disease severity. As a result, this study could assess 
correlations in male and female sex subgroups and a non-diabetic subgroup. Due to the 
retrospective nature of this study, the data collection and methods were independent of this 
analysis. As such, this limited the ability of this study to define measurements of severity, which 
may be particularly important concerning the AIP correlation with CAD, and requires further 
investigation using the GS. 
Additionally, as a number of these severity scores were categorical measurements with multiple 
levels, quantifying correlations between AIP and these measures may not best reflect 
correlations that could be obtained using continuous measures of disease severity. 
4.5 CONCLUSIONS 
 
In conclusion, this study indicates that AIP does not appear to be a marker of CAD, PAD, 
Stroke, or AAA severity in elderly New Zealanders using measures such as ABPI, PVR, CAD 
severity, CAPB, AAA, and ASI. A correlation between AIP and CAD severity may exist using 
the GS; however, this needs to be further evaluated. Therefore, whilst AIP may be significantly 
associated with the prevalence of CVD, AIP values may not be able to inform patients and 








The previous chapters of this project have demonstrated that AIP may have utility as an 
independent marker for the prevalence of CVD, however, this may not extend to inform patients 
of the severity of their respective CVD. As an extension of these findings, many patients who 
have an elevated risk for CVD, particularly elderly patients, also have an increased risk of 
having a CVD-related event. New Zealand is not exempt from this, as the current estimated 
prevalence of IHD is greater in elderly patients.4 
In support of the fact that lipid markers which incorporate LDL-C concentrations are no longer 
appropriate measures of CVD risk, meta-analyses have also established a J-shaped relationship 
between LDL-C and mortality in the elderly.103, 104 Whilst confounding factors such as statins, 
as opposed to a lack of effect produced by LDL-C, were suggested to drive this effect, these 
findings warrant the investigation into other lipid markers for CVD event outcomes. 
Presently, evidence has demonstrated that the TG/HDL-C ratio strongly predicts future risk of 
MI105. More recent work has also established prognostic associations between AIP and CVD 
outcomes across multiple ethnicities; however, these findings are conflicting based on the age 
and sex of the participants.64, 67, 106 As an example, AIP has been shown to be an independent 
prognostic marker for all-cause mortality in an elderly female cohort.64 Likewise, a relationship 
between AIP and CVD events in young and older patients with acute coronary syndrome has 
been documented, however, this was specific to male patients.106 One other finding has 
suggested that when compared with individual cholesterol risk factors, AIP may be a greater 
independent risk factor for all-cause mortality in a population based American cohort.67 
It is important to note that elderly patients are a difficult patient population for assessing CVD 
event risk due to multi-morbidity and the effects of numerous confounding factors. 
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Furthermore, as it is known that predictor-outcome associations vary among ethnic groups, 
quantifying event-risks should be performed using models tailored to specific countries.72 
Therefore, this chapter reports the results regarding the prognostic relationship between AIP 
and CVD events (MACE or all-cause mortality) in an elderly New Zealand cohort of CAD 
patients who have been previously identified with an elevated 5-year risk of a CVD event (n = 
1021). Consistent with the methods described in 2.2.3. and 2.4.3., three outcomes were 
analysed; (1) any MACE (excluding death; MACE (no death)), (2) Death (all-cause) and (3) 
any MACE or death. MACE was defined according to the American College of 
Cardiology/American Heart Association Key Data Elements and Definitions for 
Cardiovascular Endpoint Events in Clinical Trials document.82 All risk analyses for AIP were 




The demographic and outcome data are listed in Table 6. Mean follow-up in patients who did 
not incur either MACE or Deathwas 4.9 years (IQR 4.3 – 5.3), 5.0 years (IQR 4.7 – 5.4) for 
death-free patients and 5.0 years (IQR 4.6 - 5.4) for MACE-free patients. Relative to No 
MACE or Death patients, MACE patients were more likely to have a history of smoking, 
hypertension, diabetes and dyslipidaemia, higher TG and HDL-C concentrations, a larger WC 
and higher hsCRP values. MACE patients also had higher mean AIP values. Comparatively, 
there was no difference in mean values of AIP, TG or HDL-C in all-cause death patients 
compared to No MACE or Death patients. Therefore, the subsequent analysis focussed on the 
event-risk association between AIP and MACE, rather than combined MACE or Death. 
The relationship between AIP and MACE 
 
LOWESS regression was performed to identify the relationship between AIP and MACE 
(Figure 5). There was a pseudo-linear relationship between AIP and MACE, which was stronger 
at AIP values > 0.25. This effect may be driven by TG, as TG concentrations were positively 
associated with MACE until TG concentrations equal to 6 mmol/L. However, as it was 
calculated that 90% of patients had TG <2.8 mmol/L, this suggested the risk effect > 2.8 
mmol/L was specific to a small proportion of patients. By contrast, HDL-C demonstrated a 
weak negative relationship with MACE at increasing HDL-C concentrations up to 1.4mmol/L. 
Above 1.4mmol/L, the HDL-C relationship with MACE did not change. 
The optimal AIP cut-off for discriminating MACE 
 
The optimal binary AIP risk cut-off for MACE was established by identifying the value that 
maximised sensitivity and specificity using ROC curves (Supplementary Figure IV). AIP 
significantly discriminated MACE at a cut-off of 0.12 and was associated with a C-statistic of 
0.590, which encapsulated 517 and 503 patients above and below AIP = 0.12. By comparison, 
the C-statistic for AIP was similar to TG (0.590 vs 0.595, respectively), however, was greater 
than HDL-C (0.556). The TG and HDL-C cut-offs were 1.76 and 1.15 mmol/L, respectively. 
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Table 6. Demographics and clinical characteristics data in prospective outcomes patients. 
 No MACE or Death 
n = 732 
All-cause Death 
n = 121 
MACE (no death) 
n = 201 
MACE or Death 
n = 289 
P-value P-value P-value 
Portion in prospective cohort 71.7% 11.9% 19.7% 28.3%    
Age at initial recruitment, years 66.7 ± 10.2 75.7 ± 8.9 68.2 ± 10.6 70.8 ± 10.8 <.0001 .0002 .0808 
Male sex, % 61.9% 69.4% 68.1% 46.5% .1118 .0420 .1023 
History of hypertension, % 67.2% 76.9% 78.5% 50.9% .0358 .0239 .0023 
History of dyslipidaemia, % 71.4% 74.3% 84.5% 53.9% .5203 .0096 .0002 
History of diabetes, % 14.9% 38.0% 56.7% 19.3% <.0001 <.0001 <.0001 
Smoking (pack years) 
Never smoked, % 
Ex-Smoker 1 - 20 pack years, % 
Ex-Smoker > 20 pack years, % 
Current Smoker, % 



































Waist Circumference, cm 95.2 ± 14.6 96.3 ± 15.9 95.3 ± 13.0 96.7 ± 13.7 .4710 <.0001 .0722 
Body Mass Index, kg/m2 28.8 ± 5.7 28.9 ± 6.2 29.4 ± 5.0 28.8 ± 5.5 .1876 <.0001 .1428 
Total Cholesterol, mmol/L 4.2 ± 1.1 3.8 ± 1.2 4.2 ± 1.1 4.1 ± 1.1 .0025 .0559 .7407 
Triglycerides, mmol/L 1.4 (1.0 - 1.9) 1.4 (0.9 – 1.9) 1.6 (1.2 – 2.3) 1.5 (1.0 – 2.2) .4763 .0116 <.0001 
High-density lipoprotein 
cholesterol, mmol/L 
1.2 ± 0.3 1.2 ± 0.4 1.1 ± 0.3 1.1 ± 0.3 .3527 .0598 .0472 
AIP 0.1 ± 0.3 0.1 ± 0.3 0.2 ± 0.3 0.2 ± 0.3 .9588 .0036 <.0001 
hsCRP (excluding > 20) 1.7 (0.8 -1.9) 2.5 (0.9 – 7.2) 1.9 (0.7 – 4.7) 2.0 (0.9 – 4.5) .0048 .0002 .9267 
Continuous data is expressed as means ± standard deviation or median (interquartile range), with respective P-values being from one-way ANOVA or Mann- 
Whitney U-test. Nominal data is shown as percentage (%) and P-values calculated using Chi-squared tests. P < .05 was considered significant. 
Compared to the No MACE or Death cohort, patients in the MACE (no death) cohort were more likely to have a history of smoking, hypertension, diabetes 
and dyslipidaemia, were more likely to have higher concentrations of TG and HDL-C, as well as higher values of hsCRP, waist circumference and AIP. Patients 
in the All-cause Death cohort were significantly older, more likely to be male, have a history of smoking, hypertension and diabetes, and had significantly 
elevated TC concentrations compared to the no MACE or Death cohort. However, AIP values were not significantly elevated in the All-cause Death cohort 
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Figure 5. Locally weighted smoothed scatterplots showing the relationship between AIP, TG and HDL-C with MACE. 
(A) AIP values were positively associated with the probability of MACE. This relationship appeared to be more positively associated at AIP values > 0.25. (B) 
Increasing TG concentrations appeared to be positively associated with MACE until TG concentrations of 6 mmol/L. (C) A slight negative relationship existed between 
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Independent risk relationship of AIP for MACE: 
 
Subsequently, stepwise logistical regression was performed using the AIP binary cut-off to 
determine whether AIP was an independent risk factor for MACE. AIP risk groups were formed 
using patients with AIP values > 0.12. Patients with AIP values < 0.12 were used as the 
reference group. High AIP (> 0.12) was an independent risk factor for MACE in the unadjusted 
risk model. This risk effect was also retained very weakly in a model adjusted for a history of 
diabetes, hypertension and smoking (OR 1.4, Table 7). The non-diabetic subgroup analysis also 
confirmed a diabetes-independent AIP risk effect for MACE. Interestingly, further adjustment 
for a more comprehensive set of risk factors (similar to PREDICT) in the original model, 
removed the independent AIP risk for MACE. This suggested that AIP had a weak risk effect 
independent of diabetes, smoking and hypertension, however, not of a more comprehensive set 
of risk factors similar to those used in PREDICT. Interestingly, using the TG and HDL-C cut- 
offs, high TG (> 1.76 mmol/L) was also a significant risk factor for MACE in all adjusted 
models, not including the model mirroring PREDICT, while low HDL-C (< 1.15 mmol/L) only 
demonstrated an age and sex adjusted risk of MACE (Supplementary Table V). This suggest 
that TG was the harmful component of AIP driving the AIP-MACE risk effect. 
Independent prognostic value of AIP for MACE: 
 
Finally, stepwise Cox regression was performed to determine whether AIP could prognosticate 
a shorter MACE-free survival time (Table 8). Using the same risk groups as the logistical 
regression, high AIP was associated with a shorter MACE-free survival in the unadjusted model 
and a model adjusted for age and sex. Similar to the logistic regression, high AIP was associated 
with a shorter MACE-free survival in the non-diabetic Cox model adjusted for age and sex, 
despite losing independence after adjusting for diabetes alone (Figure 6; Panel B). However, 
high AIP was not an independent prognostic marker for MACE in more adjusted Cox models. 
Additionally, similar to the logistic regression, multivariable Cox regression suggested that 
high TG was the only lipid marker independently associated with a shorter MACE-free survival 
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time (Supplementary Table VI, Figure 6). High TG concentrations also appeared to be the 
harmful component of AIP, as low-HDL-C was a non-independent prognostic marker for a 
shorter MACE-free survival time after adjusting for risk factors beyond age and sex. 
Collectively, these findings suggested that whilst AIP may be a weak independent risk marker 
for MACE in the fitted logistic regression model, AIP was a non-independent prognostic 
marker for a reduced MACE-free survival. 




OR (95% confidence interval) 
P-value 
Atherogenic index in plasma 
AIP > 0.12 
 
1.8 (1.3 – 2.5) 
 
.0003 
Model 1   
Atherogenic index in plasma 
AIP > 0.12 
 
1.8 (1.3 – 2.6) 
 
.0002 
Model 2   
Atherogenic index in plasma 
AIP > 0.12 
 
1.5 (1.0 – 2.0) 
 
.0255 
Model 3   
Atherogenic index in plasma 
AIP > 0.12 
 
1.4 (1.0 – 2.0) 
 
.0475 
Model 4   
Atherogenic index in plasma 
AIP > 0.12 
 
1.3 (0.8 – 2.2) 
 
.2368 
Unadjusted model (Non-Diabetic)   
Atherogenic index in plasma 
AIP > 0.12 
 
1.9 (1.2 – 3.0) 
 
.0054 
Model 1 (Non-Diabetic)   
Atherogenic index in plasma 
AIP > 0.12 
 
1.8 (1.1 – 2.9) 
 
.0126 
P < .05 was considered significant vs AIP < 0.12. 
Data reported as odds-ratios (OR; 95% CI), with respective P-values. High AIP (> 0.12) was a risk 
factor for MACE in the unadjusted model and a model adjusted for Hx Diabetes, Hx Hypertension and 
Hx Smoking (Model 3). High AIP became a non-independent risk factor for MACE following further 
adjustment for other risk factors (Model 4). 
Model 1 – Adjusted for Age and Sex 
Model 2 – Adjusted for Hx Diabetes only. 
Model 3 – Adjusted for Hx Diabetes, Hx Hypertension and Hx Smoking only. 
Model 4 – Adjusted for Age, Sex, Hx Diabetes, Hx Dyslipidaemia, Hx Smoking, Hx Hypertension, 








HR (95% confidence interval) 
P-value 
Atherogenic index in plasma 
AIP > 0.12 
 
1.7 (1.2 – 2.2) 
 
.0005 
Model 1   
Atherogenic index in plasma 
AIP > 0.12 
 
1.7 (1.3 – 2.3) 
 
.0003 
Model 2   
Atherogenic index in plasma 
AIP > 0.12 
 
1.3 (1.0 – 1.7) 
 
.0647 
Model 3   
Atherogenic index in plasma 
AIP > 0.12 
 
1.3 (0.9 – 1.7) 
 
.1104 
Model 4   
Atherogenic index in plasma 
AIP > 0.12 
 
1.3 (0.8 – 1.9) 
 
.2678 
Unadjusted model (Non-Diabetic)   
Atherogenic index in plasma 
AIP > 0.12 
 
1.8 (1.2 – 2.8) 
 
.0068 
Model 1 (Non-Diabetic)   
Atherogenic index in plasma 
AIP > 0.12 
 
1.7 (1.1 – 2.7) 
 
.0144 
P < .05 was considered significant vs AIP < 0.12. 
Data reported as Hazards ratio (HR; 95% CI). High AIP values (> 0.12) were associated with a shorter 
MACE-free survival in an unadjusted Cox regression model and a model adjusted for age and sex 
(Model 1). High AIP did not prognosticate MACE-free survival following further adjustment for other 
risk factors (Models 3 and 4). 
Model 1 – Adjusted for Age and Sex 
Model 2 – Adjusted for Hx Diabetes only. 
Model 3 – Adjusted for Hx Diabetes, Hx Hypertension and Hx Smoking only. 
Model 4 – Adjusted for Age, Sex, Hx Diabetes, Hx Dyslipidaemia, Hx Smoking, Hx Hypertension, 
WC, TC, hsCRP (excluding > 20) and statin therapy.
 
  
*P <.05 compared to the cohort with AIP < 0.12 and the cohort with TG < 1.76 mmol/L. Comparisons between high and low risk groups, represented by the green and 
blue lines, respectively. The group with high AIP values had a significantly shorter MACE-free survival time as a raw unadjusted association (A) in the entire cohort 
and (B) within the non-diabetic sub-group adjusted for age and sex. (C) The full cohort association became non-significant when the model was adjusted for Smoking, 
Hypertension and Diabetes. (D, E and F) The same groups as (A, B and C), respectively, comparing patients with TG concentrations above and below 1.76 mmol/L. 
Patients with high TG concentrations had a significantly shorter MACE-free survival time as a raw unadjusted association (D) in the entire cohort, (E) within the non- 






As a means of quantifying the AIP-associated event-risk, this prospective study was performed 
in a series of elderly CAD patients with an elevated 5-year-event-risk (> 10%). AIP values were 
significantly elevated in the MACE, but not the death cohort. AIP also significantly 
discriminated MACE at a binary cut-off of 0.12. At this cut-off, high AIP (> 0.12) was a weak 
independent risk factor for MACE in a model adjusted for smoking, diabetes, and hypertension. 
However, high AIP was a non-independent prognostic marker of 5-year MACE-free survival 
after adjusting for these same risk factors in Cox regression. Interestingly, high TG 
concentrations (> 1.76 mmol/L) prognosticated MACE in adjusted stepwise regression and Cox 
hazards models. 
ROC analysis established that an AIP value equal to 0.12 was the optimal risk cut-off for 
discriminating MACE. Additionally, multiple logistic regression suggested that high AIP (> 
0.12) was a weak independent risk factor for MACE in the fitted stepwise logistic regression 
model. Furthermore, while some slight overfitting may have existed in the risk model mirroring 
PREDICT, and may have contributed to a non-independent risk effect, this model was created 
to simulate the AIP-MACE risk effect in a population risk model. 
Nevertheless, sole reliance on logistic regression (which measures incidence at a fixed time 
point), has been questioned as a reliable strategy for prognosticating risk, compared to methods 
that measure incidence over time and may better reflect a real-world development of CVD 
events. Therefore, this study included Cox regression models adjusted for the same risk factors 
used in the logistic regression. As AIP was a non-independent prognostic marker of 5-year 
MACE-free survival, there appeared to be a limitation to the merits of using AIP as a prognostic 
marker for MACE in elderly New Zealand CAD patients. Importantly, the prediction of 5-year 
event-risk, as opposed to a more commonly used 10-year event-risk, is based on evidence from 
RCT for CVD preventive medications, which are based on 5 years of treatment or less.19 
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Because of this, the best estimates of treatment benefit have been suggested to be over 5-year 
risk measurements and not 10 years.19 
These study findings contrast other reported prognostic associations between AIP and clinical 
outcomes. Whilst this was unexpected, the absence of an independent prognostic effect may be 
partly due to the formation of two risk groups based on a binary risk cut-off. In particular, unlike 
this study, evidence has established independent AIP risk associations with CVD events and 
mortality using multiple risk strata.51, 64, 67, 97, 106 For example, in 1997, Gaziano et al.105 first 
showed that participants with a TG/HDL-C ratio in the highest quartile had a 16-times greater 
risk of having an MI, compared to those in the lowest quartile. Similarly, more recent findings 
from the WISE study found that women in the highest AIP quartile had an independent risk 
association with MACE after adjusting for the same factors as the present study.97 Furthermore, 
other findings have also shown the top and bottom quartiles of AIP to prognosticate all-cause 
mortality in end-stage renal disease patients.51 The critical consideration from these findings is 
that the prognostic effects appear to be specific to the top quartiles of patients.51, 97, 105 
Additionally, as the range of AIP values in the highest quartile of patients from the WISE study 
was approximately equal to the range of the lower three quartiles combined; this suggested that 
a relatively small proportion of patients was eliciting a significant risk effect.97 Therefore, it 
may be that the prognostic value of AIP for MACE is limited to patients with AIP values in 
extreme quartiles. As such, a binary risk cut-off, like that used in our study, may have 
diminished a risk effect in these quartiles of AIP values. Nevertheless, LOWESS regression 
demonstrated that two broad relationships existed between AIP and MACE, supporting the 
implementation of a binary risk cut-off in this study. 
Alternatively, it is also possible that the differences in our study findings may be a consequence 
of performing this study in an elderly cohort. As stated above, elderly patients represent a 
challenging population for assessing CVD event risk, particularly due to multi-morbidity and 
the effects of numerous confounding factors. In our study, there was a significantly higher 
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prevalence of diabetes, smoking, hypertension, and dyslipidaemia in the MACE cohort 
compared to the no MACE or death cohort. Accordingly, more patients may have suffered 
MACE as a consequence of comorbid complications developed at the time of recruitment; 
therefore, MACE independent of lipid status may have been more frequent. Additionally, as 
our adjusted Cox regression models could not mitigate the effects of other strong risk factors, 
except diabetes, it suggested that other factors such as smoking and hypertension were greater 
risk factors for MACE and may have contributed to why AIP was a non-independent risk factor 
for MACE. 
In addition, the effect of age on blood TG concentrations may explain why high TG 
concentrations (> 1.76 mmol/L) were an independent prognostic factor for MACE in the 
adjusted logistic and Cox regression. Given that there was no prognostic association between 
low HDL-C concentrations (< 1.15 mmol/L) and MACE, the data also indicate that any AIP- 
MACE risk effect was likely driven predominantly by the effects of high TG concentrations. 
Furthermore, evidence has also shown that HDL-C concentrations in both men and women are 
relatively stable with age.107 By contrast, TG concentrations increase with age due to an 
increased liver synthesis of TG-rich VLDL-C, coupled with reduced expression of LDL 
receptors to catabolise VLDL-C.108 This increase in TG concentrations is also more significant 
in post-menopausal women, who, when compared to pre-menopausal women, have increased 
rates of dyslipidaemias such as HTG, which may also be secondary to other comorbidities, such 
as diabetes.109, 110 Collectively, these reasons may explain why many existing AIP event-risk 
associations have been identified in predominantly female cohorts presenting with other 
comorbidities.64, 97, 111 As such, further work is required to determine whether TG is a true risk 
factor for MACE or just a marker of increased risk in the population of geriatric patients. 
Regardless, it appears that high TG concentrations are the harmful component of AIP linking 
AIP to MACE in this study. 
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Finally, in the absence of an increase in AIP values between all-cause death and the no MACE 
or death cohort, this study did not investigate the relationship between AIP and all-cause 
mortality. Whilst it is not clear why AIP values were not significantly elevated or different 
between cohorts, a number of other studies in different population settings have established 
mortality risk relationships with higher values of AIP.64, 67 As such, it suggests that AIP may 
have utility as a mortality marker in population settings outside of New Zealand, however, it is 
not clear if this utility exists in an elderly New Zealand population. 
5.4 STRENGTHS AND LIMITATIONS 
 
The strengths of this study include the prospective study design, the large cohort comprising of 
both sexes, and the ability to adjust for relevant confounders. This study, however, was not 
without limitations. We understand that there is an inherent element of ascertainment bias 
within our study cohort, who were recruited based on having suspected CAD defined using 
coronary angiography. Therefore, subjects without suspected CAD will be underrepresented, 
and the applicability of this observation to a more generalised elderly population is unknown. 
However, it was important to establish whether AIP was first a marker of clinical outcomes in 
an at-risk population. Furthermore, the study population may not be reflective of a true 
population as, > 60% of participants in each cohort were male. Therefore, future research 
performed in a non-CAD cohort with equal proportions of both sexes may be more indicative 
of a true elderly population effect. 
5.5 CONCLUSIONS 
AIP > 0.12 did not appear to be an independent prognostic marker of 5-year-event-risk in an 
elderly NZ prospective cohort of CAD patients. The unadjusted prognostic utility that patients 
with high AIP values (> 0.12) have with MACE were likely to be a non-independent surrogate 
effect of other CVD risk factors. Interestingly, high TG concentrations (> 1.76 mmol/L) 
appeared to be the harmful component of AIP in an elderly cohort; however, more work is 
required to determine whether TG is a true population risk factor for MACE. 
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CHAPTER 6 
THE EFFECTS OF TWO 12 WEEK INTERVENTIONS ON AIP 
6.1 INTRODUCTION 
As stated in Chapter 1, much of the utility risk factors have as markers for CVD is centred on 
their ability to improve both risk model precision, as well as clinical decision-making processes 
in primary and secondary prevention for CVD. The latter of these two considerations is 
achieved mainly through the attainment of clinical endpoints resulting from targeted 
interventions for these risk factors12. Therefore, the extent to which a risk factor can be modified 
underpins much of its utility as a risk marker. Presently, lifestyle interventions are commonly 
recommended therapeutic means for reducing the risks attributed to CVD, particularly in low 
(< 5%) and moderate (5 - 15%) risk individuals.19 Of these, exercise is a well-established 
intervention to reduce CVD risk. One of the ways exercise exerts its beneficial effect is through 
modifications to the lipid profile.112 This is seen most evidently through its effects on HDL-C 
concentrations, and TG concentrations to a lesser extent.113, 114 Emerging evidence has also 
implicated the benefits of heat therapy as a simple therapeutic intervention for improving 
cardiovascular health. This has been shown through reductions in blood pressure, as well as 
improved vascular health, metabolic profile and cardiorespiratory fitness.84, 115-119 
This project, alongside previous findings which have been published prior to this study, have 
demonstrated the utility of AIP as a contemporary risk marker for CVD. As such, these findings 
warrant the exploration of potentially modifiable factors that may influence AIP. Currently, the 
existing literature has demonstrated that an acute period of aerobic exercise may have a 
therapeutic benefit on AIP, however, whether this extends to other forms of exercise is less well 
documented.120-122 Additionally, there are no studies investigating the effects of heat on AIP. 
Presently, lifestyle interventions also represent the primary mode of conservative care for 
patients with PAD. These patients have also been suggested to be a key patient group for 
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investigations regarding the beneficial cardiovascular effects of heat. This is in light of other 
more robust evidence highlighted in comprehensive reviews, demonstrating the positive 
cardiovascular adaptations which result from heat acclimation in athletes123, 124 and long-term 
health benefits of sauna bathing.125 
Given the inverse association physical activity has with CVD, as well as the emerging benefits 
of heat on CVD health, particularly in PAD patients, this study sought to investigate the 
influences of either of these two therapies on AIP. Specifically, we investigated whether AIP 
could be modified by an acute 12-week intervention of hot-water immersion therapy (Heat) or 
supervised exercise therapy (exercise) in patients with clinically diagnosed PAD in a small NZ 
cohort. As described in Chapter 2, this was performed using samples obtained from patients in 




Consistent with the methods reported in 2.3.1, 18 PAD patients in the study by Akerman et al. 
were randomised to two treatment groups: heat therapy (n = 8) or supervised exercise therapy 
(n = 10). Main experimental procedures were completed during at least two separate sessions 
and separated by ≥ 1 day. Prior to and following these experiments, whole blood samples were 
collected and stored. Lipid parameters including AIP were calculated from these samples. 
Clinical and demographic data is depicted in Table 9. Patients allocated to either heat or exercise 
interventions had no significantly different demographic and clinical characteristics. 
 
Table 9. Baseline demographics and clinical characteristics in exercise and heat patients. 
Variable Exercise 
(n = 10) 
Heat 
(n = 8) 
P-value 
Age (years) 74.4 ± 10.6 78.0 ± 8.0 .2135 
Hx Hyperlipidaemia, % 80.0% 75.0% .7998 
Hx Hypertension, % 80.0% 87.5% .6714 
Hx Type-2 diabetes 
mellitus, % 
















TC (mmol/L) 4.1 ± 1.3 4.3 ± 1.4 .6569 
TG (mmol/L) 1.3 (0.8 – 2.3) 1.3 (1.2 – 2.1) .6569 
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.2 .9292 
AIP 0.1 ± 0.4 0.1 ± 0.2 .5940 
hsCRP (mg/dl) 3.7 (1.2 – 7.7) 1.9 (1.1 – 4.7) .5940 
BMI 28.2 ± 7.2 28.1 ± 4.0 .9292 
Mean Arterial Blood 
Pressure (mm/Hg) 
 
109.5 ± 6.5 
 
106.1 ± 3.5 
 
.1826 
Walking Distance (m) 335.2 ± 64.7 353.5 ± 56.2 .5052 
Pain Free WD (m) 139.8 ± 53.3 186.6 ± 91.7 .2863 
Continuous data is expressed as means ± standard deviation or median (interquartile range), with 
respective P-values being from one-way ANOVA or Mann-Whitney U-test. Nominal data is shown as 
percentage (%) and P-values calculated using Chi-squared tests. P < .05 was considered significant. 
There were no significant differences in clinical or demographic characteristics between intervention 
groups at baseline. 
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Does Heat or Exercise change AIP values over a 12-week intervention period? 
Paired t-test analyses were performed to assess pre-and post-interventional AIP values based 
on respective treatment groups (Table 10). AIP values were not significantly different across 
the 12-week period when analysing all patients as a single cohort or as isolated intervention 
groups. Additionally, there did not appear to be any obvious trends in AIP values seen in either 
treatment group (Supplementary Figure V). Furthermore, when the effects of exercise or heat 
were investigated for HDL-C and TG concentrations, similar to AIP, there appeared to be no 
significant observable differences in TG or HDL-C concentrations following 12-weeks of either 
intervention (Table 10, Supplementary Figure V). 
As described in Akerman et al, heat and exercise generated significant improvements in 
walking distance (primary outcome measure) irrespective of treatment intervention. Both 
interventions also resulted in significant reductions in systolic, diastolic and mean arterial blood 
pressure (secondary outcome measures) over the 12-week period (P < .0001 Estimated marginal 
means; Table 11), with the greatest effect in the heat group. 
Collectively, these findings suggested that whilst heat and exercise appeared to improve MABP 
and walking distance, this benefit did not extend to AIP. This suggested that the therapeutic 
effect an acute 12-week intervention period of either heat or exercise could elicit on AIP was 
not significant. 
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Table 10. Paired lipid data at baseline and 12-weeks. 
Variable Baseline 12-weeks Δ P-value 
Atherogenic index in plasma 
Entire Cohort (n = 18) 
Exercise (n = 10) 
Heat (n = 8) 
 
0.09 ± 0.30 
0.06 ± 0.36 
0.12 ± 0.24 
 
0.13 ± 0.27 
0.11 ± 0.32 










Entire Cohort (n = 18) 
Exercise (n = 10) 
Heat (n = 8) 
 
1.14 ± 0.26 
1.16 ± 0.32 
1.12 ± 0.19 
 
1.14 ± 0.33 
1.16 ± 0.40 










Entire Cohort (n = 18) 
Exercise (n = 10) 
Heat (n = 8) 
 
1.3 (0.9 – 2.2) 
1.3 (0.8 – 2.3) 
1.3 (1.2 – 2.0) 
 
1.6 (0.9 – 2.0) 
1.6 (0.8 – 1.8) 









Data presented as means ± standard deviation or as medians (IQR) with respective P-values being from 
a student paired t-test. Compared to baseline, there was no significant change in AIP, HDL-C or TG 




Table 11. Primary and secondary outcome intervention measures pre-and post-intervention. 
Adapted from Akerman et al. 
 Exercise Heat Statistical Significance 






144 ± 53 
 
190 ± 73 
 
199 ± 91 
 












109 ± 7 
 
107 ± 7 
 
108 ± 6 
 







Values are means ± standard deviation and associated summary statistical significance parameters. 
Multiple comparisons were made using the estimated marginal means contrasts derived from the linear 
mixed models. Pairwise comparisons were made with the Hochberg-Bonferroni method. The randomly 
assigned group and time point were modelled as fixed effects, and participants (and associated 
interactions) were modelled as a random effect. Abbreviations: MABP, Mean arterial blood pressure; 
PFWD, pain-free walking distance. 
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6.3 DISCUSSION 
The primary finding from this study was that an acute 12-week intervention of either supervised 
exercise or heat therapy was not able to significantly change AIP values in PAD patients. Our 
data contrasts earlier reports which have investigated the influences of exercise on AIP. 
Multiple reports have suggested regular sustained aerobic exercise (> 90mins, 3 times/week) 
can reduce the AIP in normal and obese Chinese individuals.126, 127 This effect was also seen in 
Stranska et al., who demonstrated that an inverse relationship between aerobic exercise and 
AIP existed in middle-aged overweight Czech women.114 Furthermore, Ezeukwu et al. 
demonstrated that an acute 8-week aerobic exercise programme was also capable of 
significantly reducing AIP values in young non-obese males.121 
It was noted that the study period and frequency of exercise used in Stranska et al. was similar 
in length to our study (12 weeks, 2 sessions/week, respectively), however, it is plausible that a 
combination of patient adherence to the protocol and differences in sample size (n = 37 versus 
n = 18 in the present study) may account for the differences between our findings and those 
listed in Stranska et al. Specifically, unlike patients who are overweight exercise might be less 
tolerated in patients with PAD, who present with symptoms of claudication, limiting their time 
of engagement in exercise.128, 129 
The differences in study findings may also be reflected by the differences in patient adherence 
between this study and other reports. This is because, despite the two-session/week protocol, 
patients in Akerman et al. only attended one session per week on average whilst one patient did 
not complete part of the protocol at all.84 We note that whilst patients in Stranska et al. were 
recommended to complete exercise twice per week minimum (24 training units in total), the 
median value of training units across the study was 36. This difference highlights the disparity 
in exercise tolerability between PAD and obese patients. Therefore, coupled with a greater 
sample size, low patient adherence may also explain the differences in study findings. 
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Previous work from Venojarvi et al. has also indicated that distinct modes of exercise training 
may influence AIP differentially.122 This was reflected in their findings where reductions in 
AIP values were seen following 12-weeks of aerobic exercise, which was not seen for men who 
performed 12-weeks of resistance training. Additionally, the findings of Ezeukwu et al. were 
also compared to a group who performed 8-weeks of interval training, which did not elicit any 
significant reductions in AIP values following 8-weeks of interval training.121 Furthermore, as 
Edwards et al. have also demonstrated an inverse relationship between muscle-strengthening 
activities and high AIP values, independent of known covariates, as well as physical activity 
guidelines, these findings suggest the therapeutic effect of exercise on AIP may be limited to 
aerobic exercise.120 Unlike Venojarvi et al., where the results were obtained from middle-aged 
men with impaired glucose regulation, the use of a population-based cohort of American men 
and women in Edwards et al. may make these findings more generalisable. Nevertheless, 
regardless of these equivocal findings, there is evidence to suggest that some therapeutic effect 
exists from an acute exposure to exercise on the AIP; irrespective of the exercise protocol itself. 
Therefore, in the absence of any significant effect in this study, it is possible that a repeat 
analysis of this study using a larger sample group may yield more promising results. 
The other finding from this study was that 12-weeks of hot-water immersion therapy had little 
effect on the AIP. Presently, the literature regarding heat and blood lipids in the context of CVD 
is largely non-existent. However, our hypothesis for any potential effect of heat on the AIP was 
not centred on a known association between heat and lipids, rather by the known effects heat 
exerts as a substitute for exercise on the cardiovascular risk profile.130 Therefore, by proxy, we 
suggested this effect may extend to AIP. 
To date, much of the existing literature regarding heat therapy has been produced in healthy 
individuals, often athletes. Specifically, passive heat acclimation after, or as a substitute for 
exercise, has known benefits including lowered cardiovascular strain, improved 
thermoregulatory capacity and haemodynamic parameters.123, 124 These effects have been 
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demonstrated to occur following exposure to a number of different heat modalities, which 
generally involve either exercising in the heat or hot bath. Collectively, these have been shown 
to improve aerobic performance. 
Furthermore, in these protocols, it was highlighted that exercise was not necessary for the 
physiological adaptations to occur. As a consequence, these findings have also supported the 
use of heat in the treatment of PAD as a more well-tolerated therapeutic alternative.73 As an 
example, Tei et al. elucidated the positive effects of Waon therapy, a form of dry sauna bathing, 
on lower limb perfusion in PAD patients.115 Additionally, two groups, have demonstrated the 
acute benefits of heat mediated lower-limb perfusion using water. However, the extent of these 
benefits in both of these papers has been focussed on changes in haemodynamic parameters, 
rather than changes in blood lipids.115, 117 Moreover, as none of these papers make plausible 
suggestions for how heat may mechanistically relate to blood lipids or AIP, this suggests that 
at least in PAD patients, heat does not seem to mimic the potential therapeutic mechanisms that 
exercise has on the AIP as a therapeutic intervention. 
6.4 STRENGTHS AND LIMITATIONS 
The strengths of this analysis were the paired nature of the data, which made our comparisons 
more robust. There are however several limitations to be aware of in analysing this data. The 
first is the small sample size and hence, a significant lack of power. Whilst there were no 
observable trends in AIP values across the 12 weeks between intervention groups, whether such 
trends would exist in a larger more representative population sample and/or in non-PAD 
patients is unknown and requires further investigation. A second limitation is a lack of a control 
group; however, the design and collection of the data in Akerman et al. was independent of the 
present investigation. Moreover, Akerman et al. was designed as a proof of principle study 
using a study population where any effect of either intervention would be most apparent. As 
such, whilst a control population would have been ideal, the presence of a control population 
was not an essential part of the analysis in question. Finally, this study was a post-hoc 
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opportunistic investigation to analyse the effects of two lifestyle interventions in New Zealand 
PAD patients with readily available AIP data. Therefore, future prospectively designed research 
in other CVD cohorts which tests the effect of these and other interventions on AIP is necessary. 
Doing so may also reveal more promising therapeutic opportunities for targeting AIP as a 
potential contemporary lipid-risk marker. 
6.5 CONCLUSIONS 
 
There was no evidence of a significant difference in AIP values following an acute 12-week 
intervention of either heat or exercise in PAD patients. As such, whether continuous exercise 




THE EPIGENETICS OF AIP 
7.1 INTRODUCTION 
Prior to this chapter, the utility of AIP as a risk marker has been assessed with particular respect 
to other established environmental risk factors. Whilst dyslipidaemias are primarily a result of 
environmental factors, such as poor lifestyle decisions, a lack of physical activity and a poor 
diet, many individuals with dyslipidaemias are those with familial lipid disorders. Therefore, a 
genetic influence may also be playing a role in dyslipidaemia. As an example, familial 
hypercholesterolemia, and hypoalphalipoproteinaemia are two common familial lipid 
disorders.131, 132 As further evidence of this, in 2013, a genome-wide association study identified 
157 genetic loci associated with blood lipids, which was suggested to explain ≤12% of trait 
variance associated with blood lipid levels.133 
Collectively, these findings have prompted investigations into epigenetic mechanisms that may 
influence dyslipidaemia. DNA methylation is one specific epigenetic process, involving 
additions of a methyl group to the C5 position of cytosine to form a 5-methyl-cytosine at CpG 
sites.134 More specifically, when DNA methylation occurs at CpG sites in promoter regions of 
genes, DNA methylation can result in the activation or repression of gene transcription. DNA 
methylation changes are also heritable, reversible and responsive to the environment.134 
Therefore, for these reasons, epigenetics has been considered to be a bridge between genotype 
and phenotype.135 
Multiple epigenome-wide association studies (EWAS) have investigated associations between 
blood lipids and DNA methylation markers. CpG sites associated with genes such as ABCG1, 
CPT1A, SREBF1, and DHCR24, have consistently been identified to be involved in cholesterol 
and lipid metabolism.136 More specifically, EWAS performed in both whole blood and CD4+ 
T cells, have identified a specific methylation marker, cg06500161, annotated to the ABCG1 
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gene.137 This gene encodes ATP binding cassette subfamily G member 1 and may be of 
particular importance to AIP as it is also associated with blood levels of TG and HDL-C.138 
DNA methylation at other CpG sites, including loci associated with the CPT1A gene (encoding 
carnitine palmitoyltransferase; cg00574958, cg17058475, cg01082498, and cg09737197), and 
TXNIP (encoding thioredoxin-interacting protein), have also been shown to associate with 
blood lipid levels as well as metabolic disorders including type-2 diabetes, obesity, and 
inflammation.139, 140 Because of the direct link between CpG sites and lipid and metabolic 
diseases, this evidence has lent support to the notion that epigenetics may play an essential role 
in the underlying biology and pathology of blood lipids and CVD. 
To date, there has been no published literature investigating the epigenetic markers associated 
with AIP. If AIP is communicating an additional risk of CVD beyond individual cholesterol 
components such as TG and HDL-C, it may be that some of this disease biology is attributed 
to epigenetic markers that link AIP to CVD and other broad non-lipid affiliated CVD processes. 
Therefore, identifying the genetic factors associated with AIP may provide a more thorough 
understanding of the pathways that regulate lipoprotein composition and metabolism. In turn, 
this understanding may also shed light on the aetiology linking AIP with CVD. Based on this, 
two separate EWAS for AIP were conducted to investigate the epigenetic mechanisms 




Overview of EWAS hits associated with AIP 
 
To identify CpG sites associated with AIP, and consistent with the methods described in 2.2.4, 
EWAS data from two independent CVD cohorts were explored: 1) a discovery cohort 
consisting of male and female CVD patients, which were analysed using the 850K (850 
thousand CpG sites) EPIC array and 2) an independent replication cohort of male CVD patients, 
which were analysed using the 450K BeadChip. The number of CpG sites included in the 
analysis is thus much larger for the discovery cohort. 
First, CpG sites with a P < 0.05 were compared between the two cohorts. This was performed 
to give an overview of significant CpG sites in each cohort. At a P < 0.05, 45061 CpG sites 
were identified in the discovery cohort, which corresponded to 13,576 unique gene terms. In 
the replication cohort, 100,382 CpG sites were P < 0.05, corresponding to 18,245 unique gene 
terms. Note that the P-values were not adjusted for multiple testing; therefore, many of the hits 
with P < 0.05 will likely be false positives. 
Next, to identify whether any epigenetic markers associated with AIP were similar between 
cohorts, concordant gene terms between the two cohorts were identified. To do this, gene terms 
annotated to the top 1% of CpG sites from each cohort were compared. These were all highly 
significant (P < 0.0025) for both cohorts and corresponded to 3344 and 3980 gene terms for 
cohorts 1 and 2, respectively (Figure 7). 834 unique gene terms were also replicated between 
cohorts (Figure 7). The top 20 replicated gene terms ranked based on their position in the 
discovery cohort are listed in Table 12. As depicted in Table 12, gene terms such as ABCG1, 












Table 12. Top 20 most significantly replicated genes associated with AIP, ranked by the 
discovery cohort. 
Gene Name RANK (Discovery) P-value R2 RANK (Replication) P-value R2 
ABCG1 1 6.74E-15 0.24 1 1.37E-14 0.26 
CPT1A 2 4.36E-11 -0.20 471 4.96E-04 -0.12 
TXNIP 3 5.91E-11 -0.20 31 2.77E-05 -0.14 
DHCR24 38 5.19E-06 -0.14 262 2.62E-04 0.12 
ITK 55 7.69E-06 0.14 482 5.05E-04 -0.12 
DPCR1 59 8.60E-06 0.14 118 1.19E-04 0.13 
CD247 104 1.97E-05 0.13 166 1.66E-04 -0.13 
ZFHX3 107 2.05E-05 -0.13 447 4.60E-04 -0.12 
SLC16A3 112 2.22E-05 -0.13 43 3.73E-05 0.14 
CBS 117 2.38E-05 0.13 365 3.60E-04 -0.12 
COBL 133 2.94E-05 0.13 256 2.55E-04 -0.12 
CHN2 180 4.44E-05 0.13 325 3.22E-04 -0.12 
NOSIP 285 8.44E-05 0.12 353 3.48E-04 -0.12 
LPAR5 295 9.02E-05 0.12 286 2.85E-04 0.12 
DENND4B 306 9.44E-05 -0.12 25 1.89E-05 0.14 
LPCAT1 314 9.71E-05 0.12 284 2.84E-04 0.12 
SREBF1 363 1.17E-04 0.12 2 1.01E-07 0.18 
JPH3 409 1.43E-04 0.12 79 6.42E-05 -0.13 
MEGF6 460 1.62E-04 0.12 85 7.23E-05 -0.13 
PALM 554 2.09E-04 0.11 52 4.58E-05 0.14 
Comparison of top AIP-associated CpG sites with previously reported sites 
To determine whether AIP was reflecting the known DNA methylation biology associated 
with blood lipids and metabolic disorders, a literature search was performed using evidence 
from several reviews and meta-analyses (Dec 2016 - present) for EWAS investigating lipid 
traits and lipid-related diseases, chronic low-grade inflammation, and smoking. 
Concordant DNA methylation biology (replicated CpG sites and associated gene terms) 
between our findings and the above evidence has been listed in Table 13. 
Following this literature search, 13 CpG sites (annotated to 10 gene terms) were identified 
which have been previously identified in EWAS performed for individual blood lipid levels 
of TG, HDL-C, LDL-C and TC (some were associated with several). These CpG sites and 
annotated gene terms were also associated with; BMI, HTG, type-2 diabetes, metabolic 
syndrome and hsCRP (Table 13). No previously reported gene terms associated with smoking 
were present in our EWAS data. All gene terms and associated CpG sites annotated to ABCG1, 
SREBF1, SBNO, APOA5, and KLF13 were positively associated with AIP, whilst genes 
annotated to CPT1A, DHCR24, SARS and TXNIP were negatively associated with AIP 
across both cohorts. Functionally, the above gene terms also play broad roles in 
lipid metabolism, glucose homeostasis, and inflammation, supporting the hypothesis that 
AIP may be associated with epigenetic changes involved in broader metabolic 
processes otherwise not reflected by individual lipids. Specifically, as depicted in Table 13, 
gene terms such as SBNO2 and LY6G6E, encoding Protein strawberry notch homolog 2 
and Lymphocyte antigen 6 complex, respectively, are gene terms involved in low-grade 
inflammation, the IL-10 signalling pathway and BMI. These gene terms have not been 
identified previously in EWAS for HDL-C and TG. Thus, at the DNA level, and as a single 
risk measure, AIP seems to be reflecting the known biology associated with blood lipids 
and risk factors for CVD; some of which is independent of TG and HDL-C. 
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Table 13. Literature search of CpG sites and replicated genes associated with AIP, lipid traits, phenotypes and metabolic disorders. 
Lipid Traits Metabolic Traits Inflammation Ref 
Annotated Genes Probe ID Chr TG HDL-C LDL-C TC T2D BMI Met(s) TPP hsCRP IL-10 
ABCG1 cg06500161 
cg27243685 




11 • • • • 135, 137, 141, 142 
TXNIP cg19693031 1 • • 137, 141, 143 
SREBF1 cg11024682 17 • • • 135, 137, 141, 142 
DHCR24 cg17901584 1 • • • • 135, 137, 142 
SBNO2 cg07573872 19 • • 143, 144 
KLF13 cg12426092 15 • • 137 
SARS cg12465490 1 • • 137 
APOA5 cg12556569 11 • 141 
LY6G6E cg13123009 6 • • 143 
BMI, Body mass index; Chr, chromosome; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; IL-10, interleukin-10; LDL-C, 




Identification of enriched GO terms and biological pathways involved in AIP 
Finally, to investigate which biological pathways were associated with AIP, a combination of 
GO enrichment and pathway enrichment analysis was performed on both cohorts using 
Metascape. As described in 2.4.4 of the methods, for the discovery cohort, gene terms that met 
a stringent threshold of P < .0001 (n = 115) were included in the analysis. Likewise, for the 
replication cohort, gene terms of P < 1.0E-5 (n = 73) were included in the analysis. These cut- 
offs were an arbitrary estimate; to pick a sufficient number of most significant gene terms. 
Discovery cohort: 
In the discovery cohort, 12 enriched GO terms and pathways met a -log10P < -2.0 (Table 14, 
Figure 8). Among these pathways, GO:0042177 (Negative regulation of protein catabolic 
process), showed the most significant enrichment with AIP. Several other pathways such as; 
GO:0008610 (lipid biosynthetic process) GO:0033032 (regulation of myeloid cell apoptotic 
process) and GO:0046631 (alpha-beta T cell activation) which reflect processes involved in 
lipid synthesis and inflammation were also enriched for AIP. However, some enriched GO 
terms and pathways did not have a direct link to AIP. These included GO:0035235 (Ionotropic 
glutamate receptor signalling pathway), GO:0009069 and GO:0021537 (telencephalon 
development); pathways involved in neural signalling and neural development. 
Replication Cohort: 
16 enriched GO terms and pathways in the replication cohort, which met a -log10 P < -2.0 are 
shown in Table 15 and Figure 9. R-HSA-2559585 (Oncogene Induced Senescence), was the 
most enriched pathway associated with AIP. Several other enriched GO terms and pathways 
appeared to reflect the previously discussed biology between AIP and cardiometabolic risk 
factors. These were related to blood lipid metabolism: GO:0019216 (regulation of lipid 
metabolic process), GO:0050994 (regulation of lipid catabolic process), and R-HSA-174824 
(Plasma lipoprotein assembly, remodelling, and clearance). Several pathways related to 
inflammatory processes were also enriched, such as GO:1902106 (negative regulation of 
83 
leukocyte differentiation) and GO:0002534 (cytokine production involved in inflammatory 
response). These pathways are broadly consistent with those identified in the discovery cohort. 
Other pathways involved in the regulation of blood sugars, diabetes and obesity, cell survival, 
and cell death were also enriched (Table 15). Likewise, several pathways such as R-HSA- 
9614085 (FOXO-mediated transcription), GO:0051279 (regulation of release of sequestered 
calcium ion into cytosol) and GO:0050804 (modulation of chemical synaptic transmission) 
were upregulated in response to AIP. However, as was described for the discovery cohort, their 
exact link to AIP was not immediately apparent. These pathways are also different from those 
identified in the discovery cohort, however, this is not surprising as the coverage in the 
discovery cohort (850K sites) is greater than that of the replication (450k array). Because of 
this, as stated earlier, a greater number of CpG sites per gene term can be differentially 
methylated. This can lead to the upregulation/downregulation of genes in the 850k which would 
otherwise not be upregulated in the 450k array and can contribute to a different set of enriched 
pathways. 
Collectively, these findings suggest that the biologically enriched pathways associated with AIP 
reflect the known biology for blood lipids, non-lipid metabolic disorders and other potentially 
novel biological pathways. 
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Table 14. Biological pathways associated with AIP in the discovery cohort ranked by P-value 
Category GO ID GO Term Count -log10P -log10Q
BP GO:0042177 Negative regulation of protein catabolic 
process 
5 -4.68 -0.51
BP GO:0035235 Ionotropic glutamate receptor signalling 
pathway 
3 -4.47 -0.51
BP GO:0033032 regulation of myeloid cell apoptotic 
process 
3 -4.27 -0.49
BP GO:0009069 serine family amino acid metabolic 
process 
3 -3.61 -0.26
BP GO:1903827 regulation of cellular protein localization 7 -3.46 -0.24
BP GO:0043113 receptor clustering 3 -3.44 -0.24
BP GO:0046631 alpha-beta T cell activation 4 -3.38 -0.24
BP GO:0021537 telencephalon development 5 -3.35 -0.24
BP GO:0034504 protein localization to nucleus 5 -3.28 -0.20
BP GO:0098739 import across plasma membrane 3 -2.56 0.00 
BP GO:0008285 negative regulation of cell proliferation 7 -2.52 0.00 
BP GO:0034250 positive regulation of cellular amide 
metabolic process 
3 -2.16 0.00 
BP GO:0008610 lipid biosynthetic process 6 -2.06 0.00 
Abbreviations: BP, biological process. * P-value expressed as –log10P. 
Figure 8. Heat map of enriched pathways associated with AIP in the discovery cohort, coloured 
by P-values. 
AIP appeared to be most associated with biological pathways relating to protein catabolic processes and 
ionotropic glutamate receptor signalling. Other pathways involved in inflammation and lipid synthesis 
have also been enriched. 
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Table 15. Biological pathways associated with AIP in the replication cohort ranked by P-value 
Category GO ID GO Term Count -log10P -log10Q
REACTOME R-HSA-2559585 Oncogene Induced Senescence 3 -3.43 0 
BP GO:0019216 regulation of lipid metabolic 
process 
8 -3.43 0 
BP GO:1901264 carbohydrate derivative transport 4 -3.42 0 
BP GO:0048566 embryonic digestive tract 
development 
3 -3.39 0 
BP GO:0050804 modulation of chemical synaptic 
transmission 
8 -3.25 0 
BP GO:1902106 negative regulation of leukocyte 
differentiation 
4 -2.99 0 
BP GO:0002534 cytokine production involved in 
inflammatory response 
3 -2.89 0 
BP GO:0050994 regulation of lipid catabolic 
process 
3 -2.82 0 
REACTOME R-HSA-9614085 FOXO-mediated transcription 3 -2.57 0 
REACTOME R-HSA-174824 Plasma lipoprotein assembly, 
remodelling, and clearance 
3 -2.49 0 
BP GO:0006487 protein N-linked glycosylation 3 -2.34 0 
BP GO:0051279 regulation of release of 
sequestered calcium ion into 
cytosol 
3 -2.28 0 
BP GO:0015850 organic hydroxy compound 
transport 
5 -2.27 0 
REACTOME R-HSA-381340 Transcriptional regulation of 
white adipocyte differentiation 
3 -2.25 0 
BP GO:2001242 regulation of intrinsic apoptotic 
signalling pathway 
4 -2.25 0 
BP GO:0001942 hair follicle development 3 -2.24 0 
Abbreviations: BP, biological process. P-value expressed as –log10P. 
Figure 9. Heat map of biological pathways associated with AIP in the replication cohort, coloured 
by P-values. 
AIP appeared to be most associated with biological pathways relating to Oncogene induced Senescence, 
the regulation of lipid metabolic processes, carbohydrate derived transport, embryonic digestive tract 
development and modulation of chemical synaptic transmission. 
7.3 DISCUSSION 
The current study reports the results of the first EWAS performed for AIP. Using two 
independent CVD cohorts, DNA methylation at a single locus within ABCG1 was the top 
replicated epigenetic signature associated with AIP. Additionally, this study replicated several 
other CpG sites, which have been previously linked to traditional blood lipid levels in individual 
lipid EWAS. AIP-associated DNA methylation biology was also associated with gene terms 
and biological pathways involved in non-lipid metabolic disorders and neural signalling events. 
In this study, methylation of a CpG site (cg06500161) annotated to the ABCG1 gene was the 
top site associated with AIP in both CVD cohorts. The ABCG1 transporter, for which the 
ABCG1 gene codes for, is involved in cholesterol efflux from lipid-laden macrophages (so- 
called foam cells). Defects in the ABCG1 transporter function have been shown to lead to severe 
defects in cholesterol efflux to HDL, massive cholesterol accumulation in foam cells, and 
accelerated atherogenesis.138 Importantly, as components of AIP, both TG and HDL-C (as well 
as sdLDL by proxy) reflect mechanisms involved in arterial retention and extraction of 
cholesterol via their interaction with CETP.41 Therefore, as the processes involved in AIP and 
ABCG1 are inherently similar, it is unsurprising that ABCG1 was the topmost differentially 
methylated locus associated with AIP in both cohorts. 
Our literature search also reported concordant DNA methylation patterns at several CpG sites 
(13 in total) linked with blood lipid levels in isolated lipid EWAS, which were also associated 
with AIP. Specifically, this study identified CpG sites within ABCG1, CPT1A, TXNIP, and 
SREBF1 genes which have also been linked to levels of TG and HDL-C in whole 
blood lipid EWAS.137,141 Irvin et al. have also previously identified positive methylation 
patterns at four sites within the CPT1A gene (encoding carnitine palmitoyltransferase I) that 
are associated with blood levels of TG, VLDL-C, and LDL-C.139 Two of these same CpG 
sites have also been linked to sdLDL in EWAS for lipoprotein subfractions.145 Here, three of 
the four sites identified in Irvin et al,8 including the two sites identified in Frazier-wood et al.9 
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(cg05325763, cg00574958, and cg17058475), were replicated and associated with AIP. 
However, unlike these earlier findings, methylation levels of these sites were negatively 
associated with AIP in this study. Positive methylation of these sites within CPT1A results 
in increased synthesis of liver enzyme carnitine palmitoyltransferase, an enzyme involved 
in fatty acid oxidation and TG mobilisation; thus, reducing VLDL-C and sdLDL 
concentrations.139, 145, 146 Therefore, negative methylation at CpG sites within CPT1A 
suggests that the opposite mechanisms are occurring, driving a more atherogenic lipid profile. 
As such, this finding may offer a biological explanation for the epidemiology describing AIP 
to be a marker for a more atherogenic lipid profile.54 The small literature search also showed 
that AIP-associated DNA methylation patterns might reflect epidemiology linking AIP to 
risk factors associated with CVD, particularly BMI (obesity), diabetes, and inflammation. 
As methylation patterns at some CpG sites were not present for any or both of TG or HDL-C, 
as discussed above, this offered other biological suggestions for why AIP may be a more 
significant risk marker beyond these individual lipid markers. 
CpG sites located within genes known to influence processes associated with BMI were 
the most common in this study. The processes involved in BMI, and thus obesity, are highly 
linked to blood lipid metabolism and biosynthesis, which subsequently contributes to 
atherogenesis. Therefore, it makes sense that methylation of these loci is also associated with 
AIP. Thus, the AIP-associated DNA methylation changes seen in this study are likely a 
reflection of these processes. As an example, this study, alongside other blood EWAS 
performed for BMI, has identified increased methylation of a CpG site within the gene 
DHCR24 (encoding enzyme 24- dehydrocholesterol reductase), an enzyme regulating 
cholesterol biosynthesis in the liver.135, 147 Additionally, negative methylation of a single CpG 
site (cg19693031) annotated to TXNIP was the third-highest ranked locus in our discovery 
cohort and ranked thirty-first in our replication cohort. In the context of AIP, a strong 
association between AIP and TXNIP is important as it likely reflects the strong correlations 
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between AIP and diabetes in earlier chapters, alongside other evidence describing AIP to be a 
diagnostic marker of diabetes.60, 61 TXNIP is a gene term encoding thioredoxin-interacting 
protein, which is involved in the regulation of pancreatic cell biology, peripheral glucose 
uptake, and diabetes.148, 149 EWAS performed in whole blood and CD4+ T cells have 
identified and validated negative methylation cg19693031 with diabetes, increased fasting 
glucose and HbA1c concentrations.140, 150,151 Diabetes is also often associated with an increase 
in obesity and inflammation. Evidence has shown that the knock-out of TXNIP results in 
several other pathologies associated with metabolic syndrome and inflammation.152 As such, 
negative methylation expression of TXNIP by AIP may also result in these changes. 
Additionally, based on these consequences, changes in TXNIP expression due to changes in 
AIP may contribute more significantly to the broader risk linking AIP with CVD risk biology 
compared to other gene terms. 
Finally, using a hypothesis-free approach, GO term enrichment and pathway analysis confirmed 
that the biological pathways upregulated in response to AIP, also reflect the known biology 
discussed for individual gene terms. Interestingly, pathway analysis also suggested that AIP 
may be involved in neural signalling pathways. Specifically, pre-and post-synaptic signalling 
events associated with the ionotropic and metabotropic glutamatergic synapse. Whilst it is not 
explicitly clear how these processes are linked to AIP; it is known that lipid rafts, containing 
sphingolipids, modulate neurotransmitter and receptor presentation on the pre-and post- 
synaptic membranes of central nervous system neurons.153 Defects in these signalling processes 
also have well-established links to diseases such as Schizophrenia and Alzheimer's.154, 155 
Therefore, if AIP-associated DNA methylation patterns are involved in defects of these 
pathways, AIP may also be linked to these diseases. 
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7.4 STRENGTHS AND LIMITATIONS 
Collectively, this study has revealed biologically plausible associations between DNA 
methylation patterns and AIP; however, it should be viewed with several limitations. Due to 
the time constraints of the project, certain elements of the analysis of this EWAS have been 
omitted. An example of this, the lack of multiple testing of significant CpG sites in each cohort 
may have driven an increase in false-positive findings. Moreover, there are limitations to the 
interpretation of pathway enrichment analysis, as this type of analysis is used as a hypothesis- 
generating tool. As such, these findings may reflect an overly simplistic view of the epigenetic 
mechanisms linked to AIP. It is important to note, however, that multiple CpG sites have been 
identified and replicated at a high level of significance in two large independent CVD cohorts. 
Additionally, as these cohorts have met quality assurance tests, it suggests that our findings 
have some robustness. There are also benefits for performing EWAS in whole blood, 
particularly because blood methylation markers can often act as surrogates for markers specific 
to other effector tissues, and may explain why certain gene markers involved in the regulation 
of tissue-specific processes were upregulated. However, future research using these same 
cohorts should examine the possibility of tissue-specific methylation, which may produce 
stronger results than those identified in this study. 
7.5 CONCLUSIONS 
Epigenetics and DNA methylation play a key role in explaining a portion of the underlying 
biology and epidemiology for AIP as a CVD risk factor. These markers appear to link AIP with 
both; the existing CVD biology attributed to individual TG and HDL-C lipids, as well as 
additional risk biology unaccounted for by these isolated lipids. Collectively, these findings 
provide additional evidence to suggest that AIP may function as a more significant 




This chapter summarises the strengths, limitations, implications and future research of the entire 
project. The project findings in the context of the aims of the research have also been evaluated. 
8.1 PROJECT STRENGTHS AND LIMITATIONS 
 
The primary strength of this project was the large multiple cohort study design consisting of a 
broad spectrum of patients with clinically characterised CVD (IHD, CAD, PAD, stroke, and 
AAA) recruited over two decades. Individually, patients were recruited and classified according 
to standard practice and diagnostic guidelines. Additionally, the use of these same patient 
cohorts for separate research prior to this project has meant that the cohorts used in this project 
have passed quality assurance tests. Collectively, these measures ensured the data analysed in 
this project was of a quality sufficient to assess the primary aim of the project, which was to 
investigate the utility of AIP as a risk marker for CVD. 
This project also had limitations which must be considered. The first is the cross-sectional 
design of the project. As the large portion of patient recruitment was not performed 
prospectively, the collection of these patient cohorts was not performed with this project or the 
fulfilment of this project’s aims in mind. Whilst it was possible to fulfil the project aims, to do 
so, a significant amount of data harmonisation between cohorts was performed to reclassify 
patient groups into similar risk terms for the analysis. Therefore, the risk groups used to address 
the aims of the project may not be truly indicative of the patient populations which they 
represent and may be more representable if patient were recruited prospectively. Additionally, 
data harmonisation resulted in patients shifting between populations and between studies. 
Therefore, it is possible that the translation of the project findings may misrepresent the true 
risk association for AIP in these risk populations. Thus, a more prospectively designed cohort 
would provide an opportunity to validate these risk relationships. 
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A second limitation was the ability of our data to reflect a true elderly New Zealand population. 
Greater than 95% of patients throughout the cohorts were of European descent. As such, this 
project did not have sufficient numbers of other ethnic groups, particularly Māori and Pacific 
populations, to perform a sub-analysis of these populations. As significant health inequalities 
exist between indigenous Māori and non- Māori, and Pacific and non-Pacific populations, it is 
clear that any proposed inclusion of AIP into a New Zealand population risk model should first 
be assessed in these higher risk populations. Doing so is particularly important if we are to 
reduce the health inequalities that affect Māori and Pacific individuals and to also reflect the 
entire elderly New Zealand population. 
8.2 SUMMARY 
To minimise the global burden of CVD, efforts have been made to improve CVD risk 
modelling. Improvements in individual risk factor assessments, particularly for dyslipidaemia, 
have been crucial to improving CVD risk modelling, as current risk management strategies 
targeting dyslipidaemia reflect an overly simplistic understanding of this risk factor. This has 
been highlighted most evidently by the residual CVD risk remaining in statin-treated patients 
when LDL-C concentrations are used as a representative marker for dyslipidaemia. However, 
discoveries of non-traditional lipid markers and the strong correlations between these with other 
routinely collected lipids (such as TG and HDL-C), has suggested there may be utility in 
quantifying dyslipidaemia using TG and HDL-C. Therefore, the overall aim of this project was 
to evaluate whether AIP (log (TG/HDL-C)) has utility as an alternative contemporary risk 
marker for CVD in elderly New Zealanders. The answer is complex; the utility of AIP appears 
to be specific to certain aspects of CVD risk. 
In chapter 3, it was hypothesised that AIP would be an independent risk marker for the 
prevalence of CVD. The data indicated that AIP was a broad independent diagnostic risk marker 
for multiple forms of CVD. The discriminatory power of AIP was also greater than the 
TC/HDL-C ratio, the currently implemented ratio used in the PREDICT algorithm. It was not 
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clear in this study whether AIP was contributing an independent residual risk effect beyond TG 
or HDL-C, after these markers were include in the AIP risk model. However, some residual 
risk effect was observed, and AIP appeared to have the greatest risk effect for CVD of all 
investigated lipid parameters. Therefore, this chapter indicated that AIP may have potential as 
a more informative contemporary CVD risk marker for CVD risk modelling. 
In chapter 4, it was hypothesised that AIP would be correlated with the severity of CVDs. 
However, AIP did not clearly demonstrate utility as a marker for CVD severity, indicating that, 
whilst AIP may be significantly associated with the prevalence of CVD, AIP values may not 
be able to inform patients or clinicians about the severity of their CVD. 
Subsequently, in chapter 5, it was hypothesised that AIP would independently prognosticate 5- 
year CVD events (MACE or death). In contrast to this hypothesis, the data indicated that AIP 
values above a binary risk cut-off were not able to independently prognosticate 5-year CVD 
events in a cohort of elderly CAD patients. Rather, high TG concentrations may function as an 
independent CVD event-risk marker in the elderly. 
Furthermore, in Chapter 6, AIP values were not significantly changed in response to two 
lifestyle interventions that represent the primary mode (exercise) and an exploratory mode 
(heat) of conservative care for PAD patients. This indicated that acute lifestyle interventions of 
heat and exercise may not be therapeutically viable means of reducing the AIP-associated risk 
in elderly PAD patients. 
Finally, in Chapter 7, epigenetics and DNA methylation made plausible suggestions for the 
underlying biology associated with AIP and CVD risk biology. AIP-associated epigenetic 
mechanisms reflected the current biology for traditional lipids and other cardiometabolic risk 
factors. Additionally, as these DNA methylation patterns also identified CpG sites which were 
not present for TG or HDL-C, DNA methylation may also explain some additional biology for 
AIP. This additional biology may also be linked to the small residual risk observed in chapter 
3 and other residual risk aspects described in the literature. 
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8.3 SIGNIFICANCE AND FUTURE DIRECTIONS 
 
The findings from this project have clinical and public health implications, which should be 
considered in the context of CVD risk prediction and management. 
Primarily, Chapter 3 indicated that the inclusion of AIP into risk models, instead of the 
TC/HDL-C ratio, may have the potential to improve the discriminatory power of existing CVD 
risk prediction models (such as PREDICT, the most recent New Zealand risk model); even if 
this effect is small. This is important in an era of precision medicine where such improvements, 
even if they are minimal, are potentially beneficial. Furthermore, the eligible population for 
PREDICT includes: all men without prior CVD aged 45–74 years, all women without prior 
CVD aged 55–74 years and Māori, Pacific or South-Asian peoples from an age 15 years 
younger than these respective starting ages for men and women.19 Because of this, future 
research would benefit from the insertion of AIP into PREDICT as this would determine 
whether such an improvement in risk prediction truly exists 1) at the population level and 2) in 
ethnic subgroups who are disproportionately affected by CVD. 
As this project only tested the effects of statins and two acute-lifestyle interventions on AIP, 
future research would benefit from investigations into the effects of other therapies on AIP for 
two reasons: 
Firstly, in an age of polypharmacy, patients may be taking other pharmacological therapies, 
which may confound the AIP-CVD risk association. For example, current evidence indicates 
that AIP values are unaffected by tocilizumab treatment for patients (predominantly the elderly) 
with rheumatoid arthritis,156 however, prescribed oral contraceptives have been shown to 
significantly increase AIP by 39% over 3, 6 and 9 month periods.157 Therefore, whilst the AIP- 
CVD risk association may not be confounded by known medications commonly prescribed to 
the elderly, considerations regarding the use of other markers for pre-menopausal women who 
are eligible for CVD risk-assessment may be required. Furthermore, the evidence around the 
effects of β-blockers on TG and HDL-C concentrations is less robust.158 Therefore, as possibly 
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the most common CVD treatment, more evidence into the effects of β-blockers on AIP would 
benefit the understanding of the AIP-CVD risk effect. 
Secondly, identifying lipid-lowering therapies that can elicit a therapeutic benefit on AIP, 
particularly in the absence of a lifestyle intervention effect in this project, would be key to 
defining clinical endpoints for AIP in secondary prevention of CVD. Current evidence has 
reported that niacin and fibrate therapies, when prescribed in conjunction with a statin, 
significantly reduce AIP values (71% and 34-50%, respectively).69, 159 This project has 
demonstrated that AIP values were independent of the effects of statins. Therefore, 
confirmation of the effects of niacin and fibrates in a statin-independent drug trial would 
provide evidence of two viable therapies, which may be of great benefit to treating the AIP- 
associated CVD risk. 
8.4 CONCLUSIONS 
AIP has been suggested to be a useful risk marker for CVD in population settings outside of 
New Zealand. This project indicates that AIP may have some utility as a contemporary CVD 
risk marker for CVD risk modelling in an elderly New Zealand European population; however, 
this may be restricted to the assessment of CVD prevalence. This project has also shown that 
the TC/HDL-C ratio (the current lipid ratio used in New Zealand CVD risk modelling), 
insufficiently quantifies CVD risk compared to AIP. Therefore, AIP may have potential as an 
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Supplementary Table I. Baseline Demographics and clinical characteristics for individual CAD, PAD, Stroke, AAA and control cohorts. 
 Case populations P-values compared with control population 
 Control 
n = 958 
Case (CAD) 
n = 2610 
Case (PAD) 
n = 965 
Case (Stroke) 
n = 558 
Case (AAA) 
n = 1425 
P(CAD) P(PAD) P(Stroke) P(AAA) 
Age, years 69.0 (65.0 – 
74.0) 
69.0 (61.1 – 
76.9) 
72.8 (65.0 – 
78.1) 
74.0 (65.0 – 
80.0) 
75.0 (69.0 – 
80.0) 
<.0767 <.0001 <.0001 <.0001 
Sex, males % 68.6% 71.1% 63.5% 63.2% 79.2% <.0144 .1302 .4001 <.0001 
History hypertension, % 26.9% 63.3% 66.9% 63.2% 57.1% <.0001 <.0001 <.0001 <.0001 
History diabetes, % 5.3% 20.1% 21.0% 19.2% 11.4% <.0001 <.0001 <.0001 <.0001 
History dyslipidaemia, % 25.9% 67.8% 54.3% 57.3% 51.1% <.0001 <.0001 <.0001 <.0001 
BMI 26.2 ± 3.7 28.1 ± 5.1 26.3 ± 5.1 27.4 ± 5.8 26.0 ± 5.9 <.0001 .5756 <.0001 .5312 
Waist (cm) 95.6 ± 11.1 98.0 ± 13.0 96.5 ± 12.5 100.0 ± 12.5 98.8 ± 12.1 <.0001 .3666 <.0001 <.0001 
Waist hip ratio 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 .0042 .2670 .2106 .1042 
Pack years 0.0 (0.0 – 15.0) 13.0 (0.0 – 35.0) 26.3 (9.8 – 45.0) 15.0 (0.0 – 38.9) 25.0 (7.0 – 44.0) <.0001 <.0001 <.0001 <.0001 
Smoking Status          
Never smoked 49.6% 30.9% 16.9% 27.0% 15.8% <.0001 <.0001 <.0001 <.0001 
Ex-Smoker 1 - 20 pack 
years 
26.4% 22.9% 15.2% 18.1% 18.7% <.0001 <.0001 <.0001 <.0001 
Ex-Smoker > 20 pack years 18.3% 35.3% 41.4% 32.8% 43.8% <.0001 <.0001 <.0001 <.0001 
Current Smoker 3.8% 10.6% 24.2% 13.4% 17.5% <.0001 <.0001 <.0001 <.0001 
Blood lipids          
Total Cholesterol, mmol/L 5.3 ± 1.1 4.4 ± 1.1 4.9 ± 1.2 4.7 ± 1.2 4.9 ± 1.3 <.0001 <.0001 <.0001 <.0001 
HDL, mmol/L 1.4 ± 0.4 1.1 ± 0.3 1.3 ± 0.6 1.2 ± 0.4 1.1 ± 0.4 <.0001 .1774 <.0001 <.0001 
TG, mmol/L 1.4 (1.0 – 2.0) 1.6 (1.1 – 2.2) 1.8 (1.3 – 2.5) 1.6 (1.2 – 2.2) 1.7 (1.2 – 2.3) <.0001 <.0001 <.0001 <.0001 
AIP 0.1 ± 0.3 0.2 ± 0.3 0.2 ± 0.3 0.2 ± 0.3 0.2 ± 0.3 <.0001 <.0001 <.0001 <.0001 
hsCRP (excluding > 20) 1.5 (0.7 – 2.9) 2.4 (1.2 – 5.3) 3.3 (1.5 – 6.3) 3.2 (1.4 – 6.6) 3.3 (1.7 – 6.2) <.0001 <.0001 <.0001 <.0001 
Continuous data is expressed as means ± standard deviation or median (interquartile range), with respective P-values being from one-way ANOVA or Mann- 
Whitney U-test. Nominal data is shown as percentage (%) and P-values calculated using Chi-squared test. P < .05 was considered significant. 
Mean AIP values were significantly elevated across all individual CVD cohorts. With the exception of age in the CAD cohort, HDL-C and Waist circumference in the 
PAD population, male sex in PAD and stroke populations, BMI in PAD and AAA cohorts, and waist to hip ratio in the all cohorts except CAD, all demographic and 







































Supplementary Figure I. Box plot demonstrating the association between medicated statin exposure and total cholesterol, AIP, TG, and HDL-C in combined 
Statin groups. *P <.0005 versus non-statin medicated individuals in matching case/control groups. (A) Statin medicated participants had significantly lower TC 
concentrations compared to those who were not on a statin medication at time of recruitment in both case and control groups. (B & C) The same groups as A but 
comparing AIP and TG values, respectively. There was no significant difference in AIP values or TG concentrations between non-statin medicated and medicated 
statin groups. (D) The same groups as in graph A but comparing HDL-C concentrations. There was a reduction in HDL-C concentrations between statin-medicated 














































































Supplementary Figure II. Locally weighted smoothed scatterplot showing the relationship between AIP and coronary artery disease, peripheral arterial disea 
Stroke and Abdominal aortic aneurysm prevalence. AIP values were positively associated with the probability of having (A) CAD, (B) PAD, (C) Stroke and ( 
AAA. Interestingly, in (B) there was a constant probability of having PAD at negative AIP values, which became positive at AIP values around the 0 value. n = 327 
1925, 1488 and 2383 for CAD, PAD, Stroke and AAA, respectively. 
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Supplementary Table II. Multiple logistic regression for risk factors associated with coronary artery disease peripheral arterial disease, stroke and 
abdominal aortic aneurysm. 
 Probability of CAD  Probability of PAD  Probability of Stroke  Probability of AAA 
Unadjusted Model OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value  OR (95% CI) P-value 
Atherogenic index in plasma 
AIP > -0.039 
 












2.1 (1.8 – 2.5) 
 
<.0001 
Model 1         
Atherogenic index in plasma 
AIP > -0.039 
 












2.4 (2.0 – 2.9) 
 
<.0001 
Model 2         
Atherogenic index in plasma 
AIP > -0.039 
 












2.1 (1.5 – 3.0) 
 
<.0001 
Model 3         
Atherogenic index in plasma 
AIP > -0.039 
 












2.6 (1.8 – 3.9) 
 
<.0001 
Model 4         
Atherogenic index in plasma 
AIP > -0.039 
 












1.3 (0.8 – 2.3) 
 
.2877 
P < .05 was considered significant versus low AIP cohort (< -0.039). 
Data presented as odds-ratio (OR 95% CI), with respective P-values. High AIP was a significant independent risk factor for all forms of CVD in unadjusted and 
adjusted stepwise logistical regression models except Model 4. Model 4 was further adjusted for TG and HDL-C concentrations (continuous). 
In 2 multivariable models have reduced patient numbers relative to unadjusted models, n = 2064, 1007 and 1117 for CAD, PAD, Stroke and AAA case cohorts, 
respectively. 
Model 1 - Adjusted for age and sex. 
Model 2 - Adjusted for a history of hypertension, smoking, WC, hsCRP (excluding > 20), total cholesterol and statin therapy. 
Model 3 - Model 2 further adjusted for a history of, dyslipidaemia, age and sex. 









Supplementary Table III. Baseline Demographics and clinical characteristics of Diabetic and 
non-Diabetic groups in the combined any CVD & control cohort. 
 
 Non-Diabetic 
n = 4195 
Diabetic 
n = 814 
P-value 
Age, years 70.7 (64.0 – 77.0) 71.3 (64.0 – 77.0) .2903 
Sex, males % 70.7% 67.6% .0719 
History hypertension, % 50.0% 72.9% <.0001 
History dyslipidaemia, % 48.0% 68.9% <.0001 
BMI 26.7 ± 4.8 29.4 ± 5.5 <.0001 
Waist (cm) 96.8 ± 11.8 102.2 ± 14.1 <.0001 
Waist hip ratio 0.9 ± 0.1 1.0 ± 0.1 <.0001 
Pack years, 12.5 (0.0 – 32.0) 20.0 (0.0 – 40.0) <.0001 
Smoking Status    
Never smoked, % 31.6% 25.8% <.0001 
Ex-Smoker 1 - 20 pack years, % 22.3% 19.0% <.0001 
Ex-Smoker > 20 pack years, % 31.2% 38.7% <.0001 
Current Smoker, % 12.9% 14.3% <.0001 
Blood lipids    
Total Cholesterol, mmol/L 4.9 ± 1.2 4.4 ± 1.1 <.0001 
HDL, mmol/L 1.2 ± 0.4 1.0 ± 0.4 <.0001 
TG, mmol/L 1.5 (1.1 – 2.2) 1.9 (1.3 – 2.6) <.0001 
AIP 0.1 ± 0.3 0.3 ± 0.3 <.0001 
hsCRP (excluding > 20) 2.3 (1.1 – 4.8) 3.0 (1.3 – 6.0) <.0001 
Continuous data is expressed as means ± standard deviation or median (interquartile range), with 
respective P-values being from one-way ANOVA or Mann-Whitney U-test. Nominal data is shown as 
percentage (%) and P-values calculated using Chi-squared tests. P < .05 was considered significant. 
With the exception of TC, which was significantly lower in the diabetic cohort compared to the non- 
diabetic cohort, all demographic and clinical characteristics were elevated in the diabetic cohort 















Supplementary Table IV. Multiple logistic regression for risk factors associated with coronary artery disease peripheral arterial disease, stroke and 
abdominal aortic aneurysm in a non-diabetic cohort. 
 Probability of CAD  Probability of PAD  Probability of Stroke  Probability of AAA 
Unadjusted Model OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value  OR (95% CI) P-value 
Atherogenic index in plasma 
AIP > -0.039 
 












2.7 (2.3 – 3.3) 
 
<.0001 
Model 1         
Atherogenic index in plasma 
AIP > -0.039 
 












3.2 (2.6 – 3.9) 
 
<.0001 
Model 2         
Atherogenic index in plasma 
AIP > -0.039 
 












2.2 (1.5 – 3.2) 
 
<.0001 
Model 3         
Atherogenic index in plasma 
AIP > -0.039 
 












2.8 (1.8 – 4.2) 
 
<.0001 
Model 4         
Atherogenic index in plasma 
AIP > -0.039 
 












1.3 (0.7 – 2.2) 
 
.3226 
P < .05 was considered significant versus low AIP cohort (< -0.039). 
Data reported as odds-ratios (OR; 95% CI), with respective P-values. High AIP was a significant independent risk factor for all forms of CVD in all unadjusted and 
adjusted stepwise logistical regression models in a non-diabetic cohort except Model 4. Model 4 was further adjusted for TG and HDL-C concentrations 
(continuous). 
In 2 multivariable models have reduced patient numbers relative to unadjusted models, n = 1699, 894 and 1016 for CAD, PAD, Stroke and AAA case cohorts, 
respectively. 
Model 1 - Adjusted for age and sex. 
Model 2 - Adjusted for a history of hypertension, smoking, WC, hsCRP (excluding > 20), total cholesterol and statin therapy. 
Model 3 - Model 2 further adjusted for a history of, dyslipidaemia, age and sex. 
































Control, n = 958 1VD, n = 540 2VD, n = 458 3VD, n = 414 
 
-.4 
Supplementary Figure III. Box plot demonstrating the relationship between Coronary artery 
disease severity and AIP in controls and patients with single (1VD), double (2VD) or triple vessel 
disease (3VD). *P <.05 compared to the control population. Compared to the control population, 
patients with any form of vessel disease had significantly higher AIP values. AIP values were not 
significantly different between patient groups with any (single, double or triple) vessel disease, nor 
were there any visible trends in differences of AIP values between these groups (P = 0.41). A Kruskal- 
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Supplementary Figure IV. ROC curves for lipid parameters associated with MACE. Data presented as binary cut-offs (sensitivity – specificity) and AUC (95% 
CI). The cut-off value for AIP, which maximised sensitivity and specificity (intersection of lines) was an AIP = 0.12 and was attributed to a C-statistic of 0.590. 









1.15 (63.2 – 48.3) 












OR (95% confidence interval) 
P-value 
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.9 (1.4 – 2.6) 
 
<.0001 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L 
 
1.6 (1.1 – 2.1) 
 
.0055 
Model 1   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
2.0 (1.4 – 2.7) 
 
<.0001 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L 
 
1.5 (1.1 – 2.1) 
 
.0117 
Model 2   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.6 (1.1 – 2.2) 
 
.0106 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L 
 
1.2 (0.8 – 1.7) 
 
.3506 
Model 3   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.5 (1.1 – 2.2) 
 
.0183 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L* 
 
1.2 (0.8 – 1.7) 
 
.3572 
Model 4   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.4 (0.9 – 2.3) 
 
.1711 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L* 
 
1.0 (0.6 – 1.7) 
 
.8783 
Unadjusted model (Non-Diabetic)   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.9 (1.2 – 3.0) 
 
.0060 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L 
 
1.4 (0.9 – 2.2) 
 
.1447 
Model 1 (Non-Diabetic)   
Triglycerides, mmol/L 
TG > 1.76 mmol/L 
 
1.9 (1.2 – 3.0) 
 
.0087 
High-density lipoprotein cholesterol, mmol/L 
HDL-C < 1.15 mmol/L 
 
1.2 (0.8 – 2.0) 
 
.4200 
P < .05 was considered significant vs TG < 1.76 and HDL-C > 1.15 mmol/L. 
 
Data reported as Odds ratio (OR; 95% CI) with respective P-values. Compared to low TG concentrations 
(< 1.76 mmol/L), High TG concentrations (> 1.76 mmol/L) were a significant risk factor for MACE in 
all adjusted stepwise logistical regression models, except Model 4. Low HDL-C concentrations (< 1.15 
mmol/L) were a risk factor for MACE compared to patients with HDL-C values >1.15mmol/L in 
unadjusted models and models adjusted for age and sex (Model 1). 
 
Model 1 – Adjusted for Age and Sex. 
Model 2 – Adjusted for Hx Diabetes. 
Model 3 – Adjusted for Hx Diabetes, Hx Dyslipidaemia and Smoking status. * HDL-C met exclusion 
criteria after adjustment for diabetes and dyslipidaemia, thus model 3 is only Adjusted for 
diabetes and dyslipidaemia. 
Model 4 – Age, Sex, history of diabetes, dyslipidaemia, hypertension, smoking, WC, total cholesterol, 
hsCRP (excluding > 20) and statin therapy. 
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Supplementary Table VI. Cox proportional hazards regression analysis for effects of lipid 




HR (95% confidence interval) 
P-value 
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.7 (1.3 – 2.3) 
 
.0001 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.5 (1.1 – 2.0) 
 
.0055 
Model 1   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.8 (1.3 – 2.3) 
 
<.0001 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.5 (1.1 – 2.0) 
 
.0105 
Model 2   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.4 (1.0 – 1.8) 
 
.0248 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.1 (0.8 – 1.4) 
 
.6675 
Model 3   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.4 (1.0 – 1.8) 
 
.0392 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.0 (0.8 – 1.4) 
 
.6520 
Model 4   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.3 (0.9 – 1.9) 
 
.2067 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.0 (0.7 – 1.5) 
 
.8215 
Unadjusted model (Non -Diabetic)   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.8 (1.1 – 2.7) 
 
.0085 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.4 (0.9 – 2.1) 
 
.1394 
Unadjusted model (Non -Diabetic)   
Triglycerides mmol/L 
TG > 1.76 mmol/L 
 
1.7 (1.1 – 2.7) 
 
.0108 
High-density lipoprotein cholesterol mmol/L 
HDL-C < 1.15 mmol/L 
 
1.2 (0.8 – 1.9) 
 
.3902 
P < .05 was considered significant vs TG < 1.76 and HDL-C > 1.15 mmol/L. 
 
Data reported as Hazards ratio (HR; 95% CI) with respective P-values. Compared low TG 
concentrations (< 1.76 mmol/L), patients with high TG concentrations (> 1.76 mmol/L) were a 
significant prognostic marker for a shorter MACE-free survival time in all adjusted stepwise Cox 
regression models, except Model 4. Low HDL-C concentrations (< 1.15 mmol/L) were a significant 
prognostic marker for a shorter MACE-free survival time compared to patients with HDL-C values > 
1.15mmol/L only in unadjusted and adjusted logistical regression models for age and sex (Model 1). 
 
Model 1 – Adjusted for Age and Sex. 
Model 2 – Adjusted for Hx Diabetes. 
Model 3 – Adjusted for Hx Diabetes Hx Dyslipidaemia and Smoking status. 
Model 4 – Age, Sex, history of diabetes, dyslipidaemia, hypertension, smoking, WC, total cholesterol, 
hsCRP (excluding > 20) and statin therapy. 
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Supplementary Figure V. Paired lipid data pre-and post-exercise or heat interventions. 
